



## Clinical trial results:

### A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects with Advanced Solid Tumors

#### Summary

EudraCT number	2018-004568-72
Trial protocol	FR ES
Global end of trial date	03 March 2025

#### Results information

Result version number	v1 (current)
This version publication date	02 July 2025
First version publication date	02 July 2025

#### Trial information

##### Trial identification

Sponsor protocol code	ASTX029-01
-----------------------	------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03520075
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Taiho Oncology, Inc.
Sponsor organisation address	101 Carnegie Center, Suite 101, Princeton, NJ, United States, 08540
Public contact	Senior Study Manager, Taiho Oncology, Inc., +1 844-878-2446 , medicalinformation@taihooncology.com
Scientific contact	Senior Study Manager, Taiho Oncology, Inc., +1 844-878-2446 , medicalinformation@taihooncology.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

Analysis stage	Final
Date of interim/final analysis	03 March 2025
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	03 March 2025
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

Main objective of the trial:

The main objective of this study was to assess safety and to identify the maximum tolerated dose (MTD), the recommended Phase 2 (RP2D), and the recommended dosing regimen of ASTX029 in Phase 1 Part A (Dose Escalation) and Part B (Dose Expansion) and to assess preliminary clinical activity, as determined by ORR in tumors characterized by gene aberrations in the MAPK signal pathway that may confer sensitivity to ASTX029 in Phase 2.

Protection of trial subjects:

All study subjects were required to read and sign an Informed Consent Form (ICF).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	07 May 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

---

**Population of trial subjects****Subjects enrolled per country**

Country: Number of subjects enrolled	Spain: 16
Country: Number of subjects enrolled	France: 18
Country: Number of subjects enrolled	United Kingdom: 15
Country: Number of subjects enrolled	United States: 141
Worldwide total number of subjects	190
EEA total number of subjects	34

Notes:

---

**Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	97

From 65 to 84 years	91
85 years and over	2

## Subject disposition

### Recruitment

Recruitment details:

Subjects took part at regional sites in United States (US), France, Spain, and United Kingdom (UK) from 07 May 2018 to 03 March 2025.

### Pre-assignment

Screening details:

A total of 192 subjects were enrolled in the study to receive ASTX029, of which 2 subjects died before receiving treatment. The study consisted of 2 phases: Phase 1: Cohorts 1-12 in Part A (Dose Escalation) and a single cohort for Part B (Dose Expansion) and Phase 2: Cohorts A to F.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Phase 1A: Cohort 1 Dose Escalation

Arm description:

Subjects received ASTX029 10 milligrams (mg), powder in bottle (PiB), orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.

Arm type	Experimental
Investigational medicinal product name	ASTX029
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and effervescent powder for oral suspension
Routes of administration	Oral use

Dosage and administration details:

Subjects received ASTX029 10 mg, PiB, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.

<b>Arm title</b>	Phase 1A: Cohort 2 Dose Escalation
------------------	------------------------------------

Arm description:

Subjects received ASTX029 20 mg, PiB, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.

Arm type	Experimental
Investigational medicinal product name	ASTX029
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and effervescent powder for oral suspension
Routes of administration	Oral use

Dosage and administration details:

Subjects received ASTX029 20 mg, PiB, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.

<b>Arm title</b>	Phase 1A: Cohort 3 Dose Escalation
------------------	------------------------------------

Arm description:

Subjects received ASTX029 60 mg, PiB, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	ASTX029
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and effervescent powder for oral suspension
Routes of administration	Oral use
Dosage and administration details:	
Subjects received ASTX029 60 mg, PiB, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
<b>Arm title</b>	Phase 1A: Cohort 4 Dose Escalation
Arm description:	
Subjects received ASTX029 120 mg, PiB, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
Arm type	Experimental
Investigational medicinal product name	ASTX029
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and effervescent powder for oral suspension
Routes of administration	Oral use
Dosage and administration details:	
Subjects received ASTX029 120 mg, PiB, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
<b>Arm title</b>	Phase 1A: Cohort 5 Dose Escalation
Arm description:	
Subjects received ASTX029 200 mg, orally, PiB, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
Arm type	Experimental
Investigational medicinal product name	ASTX029
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and effervescent powder for oral suspension
Routes of administration	Oral use
Dosage and administration details:	
Subjects received ASTX029 200 mg, PiB, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
<b>Arm title</b>	Phase 1A: Cohort 6 Dose Escalation
Arm description:	
Subjects received ASTX029 80 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
Arm type	Experimental
Investigational medicinal product name	ASTX029
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Subjects received ASTX029 80 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
<b>Arm title</b>	Phase 1A: Cohort 7 Dose Escalation
Arm description:	
Subjects received ASTX029 120 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
Arm type	Experimental

Investigational medicinal product name	ASTX029
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Subjects received ASTX029 120 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
<b>Arm title</b>	Phase 1A: Cohort 8 Dose Escalation
Arm description:	
Subjects received ASTX029 40 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
Arm type	Experimental
Investigational medicinal product name	ASTX029
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Subjects received ASTX029 40 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
<b>Arm title</b>	Phase 1A: Cohort 9 Dose Escalation
Arm description:	
Subjects received ASTX029 80 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
Arm type	Experimental
Investigational medicinal product name	ASTX029
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Subjects received ASTX029 80 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
<b>Arm title</b>	Phase 1A: Cohort 10 Dose Escalation
Arm description:	
Subjects received ASTX029 120 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
Arm type	Experimental
Investigational medicinal product name	ASTX029
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Subjects received ASTX029 120 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
<b>Arm title</b>	Phase 1A: Cohort 11 Dose Escalation
Arm description:	
Subjects received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
Arm type	Experimental

Investigational medicinal product name	ASTX029
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Subjects received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
<b>Arm title</b>	Phase 1A: Cohort 12 Dose Escalation
Arm description:	
Subjects received ASTX029 280 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
Arm type	Experimental
Investigational medicinal product name	ASTX029
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Subjects received ASTX029 280 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
<b>Arm title</b>	Phase 1B Dose Expansion
Arm description:	
Subjects received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
Arm type	Experimental
Investigational medicinal product name	ASTX029
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Subjects received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
<b>Arm title</b>	Phase 2: Cohort A
Arm description:	
Subjects with neuroblastoma RAS (NRAS)-mutant melanoma received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.	
Arm type	Experimental
Investigational medicinal product name	ASTX029
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Subjects received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.	
<b>Arm title</b>	Phase 2: Cohort B
Arm description:	
Subjects with Kirsten RAS (KRAS)-mutant or KRAS-amplified non-small cell lung cancer (NSCLC) received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.	
Arm type	Experimental

Investigational medicinal product name	ASTX029
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Subjects received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.

<b>Arm title</b>	Phase 2: Cohort C
------------------	-------------------

**Arm description:**

Subjects with B isoform of RAF kinase (BRAF) V600-mutant cancers (non-colorectal cancers) received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.

Arm type	Experimental
Investigational medicinal product name	ASTX029
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Subjects received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.

<b>Arm title</b>	Phase 2: Cohort D
------------------	-------------------

**Arm description:**

Subjects with BRAF-fusion cancers received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.

Arm type	Experimental
Investigational medicinal product name	ASTX029
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Subjects received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.

<b>Arm title</b>	Phase 2: Cohort E
------------------	-------------------

**Arm description:**

Subjects with gynecological cancers with alterations in the mitogen-activated protein kinase (MAPK) pathway received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.

Arm type	Experimental
Investigational medicinal product name	ASTX029
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Subjects received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.

<b>Arm title</b>	Phase 2: Cohort F
------------------	-------------------

**Arm description:**

Subjects with tumors that were characterized by other gene aberrations (that upregulate the MAPK



signal pathway) received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.

Arm type	Experimental
Investigational medicinal product name	ASTX029
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.

Number of subjects in period 1	Phase 1A: Cohort 1 Dose Escalation	Phase 1A: Cohort 2 Dose Escalation	Phase 1A: Cohort 3 Dose Escalation
Started	3	3	3
Completed	0	0	0
Not completed	3	3	3
Death	2	2	3
Lost to Follow-up	-	1	-
Complete Consent Withdrawal	1	-	-
Study Terminated by Sponsor	-	-	-

Number of subjects in period 1	Phase 1A: Cohort 4 Dose Escalation	Phase 1A: Cohort 5 Dose Escalation	Phase 1A: Cohort 6 Dose Escalation
Started	5	10	6
Completed	0	0	0
Not completed	5	10	6
Death	2	6	4
Lost to Follow-up	1	1	-
Complete Consent Withdrawal	2	3	2
Study Terminated by Sponsor	-	-	-

Number of subjects in period 1	Phase 1A: Cohort 7 Dose Escalation	Phase 1A: Cohort 8 Dose Escalation	Phase 1A: Cohort 9 Dose Escalation
Started	3	3	3
Completed	0	0	0
Not completed	3	3	3
Death	3	2	3
Lost to Follow-up	-	-	-
Complete Consent Withdrawal	-	1	-
Study Terminated by Sponsor	-	-	-

Number of subjects in period 1	Phase 1A: Cohort 10 Dose Escalation	Phase 1A: Cohort 11 Dose Escalation	Phase 1A: Cohort 12 Dose Escalation
Started	3	7	7
Completed	0	1	0
Not completed	3	6	7

Death	1	5	7
Lost to Follow-up	-	1	-
Complete Consent Withdrawal	1	-	-
Study Terminated by Sponsor	1	-	-

Number of subjects in period 1	Phase 1B Dose Expansion	Phase 2: Cohort A	Phase 2: Cohort B
Started	20	32	15
Completed	1	6	0
Not completed	19	26	15
Death	11	20	13
Lost to Follow-up	1	-	1
Complete Consent Withdrawal	4	-	1
Study Terminated by Sponsor	3	6	-

Number of subjects in period 1	Phase 2: Cohort C	Phase 2: Cohort D	Phase 2: Cohort E
Started	12	9	32
Completed	0	0	5
Not completed	12	9	27
Death	9	5	14
Lost to Follow-up	1	-	-
Complete Consent Withdrawal	2	1	3
Study Terminated by Sponsor	-	3	10

Number of subjects in period 1	Phase 2: Cohort F
Started	14
Completed	0
Not completed	14
Death	11
Lost to Follow-up	1
Complete Consent Withdrawal	2
Study Terminated by Sponsor	-

## Baseline characteristics

### Reporting groups

Reporting group title	Phase 1A: Cohort 1 Dose Escalation
Reporting group description: Subjects received ASTX029 10 milligrams (mg), powder in bottle (PiB), orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
Reporting group title	Phase 1A: Cohort 2 Dose Escalation
Reporting group description: Subjects received ASTX029 20 mg, PiB, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
Reporting group title	Phase 1A: Cohort 3 Dose Escalation
Reporting group description: Subjects received ASTX029 60 mg, PiB, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
Reporting group title	Phase 1A: Cohort 4 Dose Escalation
Reporting group description: Subjects received ASTX029 120 mg, PiB, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
Reporting group title	Phase 1A: Cohort 5 Dose Escalation
Reporting group description: Subjects received ASTX029 200 mg, orally, PiB, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
Reporting group title	Phase 1A: Cohort 6 Dose Escalation
Reporting group description: Subjects received ASTX029 80 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
Reporting group title	Phase 1A: Cohort 7 Dose Escalation
Reporting group description: Subjects received ASTX029 120 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
Reporting group title	Phase 1A: Cohort 8 Dose Escalation
Reporting group description: Subjects received ASTX029 40 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
Reporting group title	Phase 1A: Cohort 9 Dose Escalation
Reporting group description: Subjects received ASTX029 80 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
Reporting group title	Phase 1A: Cohort 10 Dose Escalation
Reporting group description: Subjects received ASTX029 120 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
Reporting group title	Phase 1A: Cohort 11 Dose Escalation
Reporting group description: Subjects received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
Reporting group title	Phase 1A: Cohort 12 Dose Escalation
Reporting group description: Subjects received ASTX029 280 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
Reporting group title	Phase 1B Dose Expansion
Reporting group description: Subjects received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	

Reporting group title	Phase 2: Cohort A
Reporting group description: Subjects with neuroblastoma RAS (NRAS)-mutant melanoma received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.	
Reporting group title	Phase 2: Cohort B
Reporting group description: Subjects with Kirsten RAS (KRAS)-mutant or KRAS-amplified non-small cell lung cancer (NSCLC) received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.	
Reporting group title	Phase 2: Cohort C
Reporting group description: Subjects with B isoform of RAF kinase (BRAF) V600-mutant cancers (non-colorectal cancers) received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.	
Reporting group title	Phase 2: Cohort D
Reporting group description: Subjects with BRAF-fusion cancers received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.	
Reporting group title	Phase 2: Cohort E
Reporting group description: Subjects with gynecological cancers with alterations in the mitogen-activated protein kinase (MAPK) pathway received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.	
Reporting group title	Phase 2: Cohort F
Reporting group description: Subjects with tumors that were characterized by other gene aberrations (that upregulate the MAPK signal pathway) received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.	

Reporting group values	Phase 1A: Cohort 1 Dose Escalation	Phase 1A: Cohort 2 Dose Escalation	Phase 1A: Cohort 3 Dose Escalation
Number of subjects	3	3	3
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years			
arithmetic mean	69.3	57.7	56.7
standard deviation	± 2.52	± 9.50	± 10.12
Gender categorical Units: Subjects			
Female	3	2	2
Male	0	1	1

Ethnicity			
Units: Subjects			
Not of Hispanic, Latino/a, or Spanish origin	2	3	3
Missing	0	0	0
Hispanic, Latino/a, or Spanish origin	1	0	0
Race			
Units: Subjects			
Asian	0	0	0
American Indian or Alaskan Native	0	0	0
Black or African American	0	2	0
Native Hawaiian and Pacific Islander	0	0	0
White	3	1	3
Other	0	0	0
Not reported	0	0	0
Multiple	0	0	0
Unknown	0	0	0

Reporting group values	Phase 1A: Cohort 4 Dose Escalation	Phase 1A: Cohort 5 Dose Escalation	Phase 1A: Cohort 6 Dose Escalation
Number of subjects	5	10	6
Age categorical			
Units: Subjects			
In utero			
Preterm newborn infants (gestational age < 37 wks)			
Newborns (0-27 days)			
Infants and toddlers (28 days-23 months)			
Children (2-11 years)			
Adolescents (12-17 years)			
Adults (18-64 years)			
From 65-84 years			
85 years and over			
Age continuous			
Units: years			
arithmetic mean	57.6	62.8	61.0
standard deviation	± 5.22	± 8.82	± 6.72
Gender categorical			
Units: Subjects			
Female	5	6	3
Male	0	4	3
Ethnicity			
Units: Subjects			
Not of Hispanic, Latino/a, or Spanish origin	5	10	5
Missing	0	0	0
Hispanic, Latino/a, or Spanish origin	0	0	1
Race			
Units: Subjects			
Asian	1	0	0
American Indian or Alaskan Native	0	0	0
Black or African American	0	1	0

Native Hawaiian and Pacific Islander	0	0	0
White	4	9	6
Other	0	0	0
Not reported	0	0	0
Multiple	0	0	0
Unknown	0	0	0

Reporting group values	Phase 1A: Cohort 7 Dose Escalation	Phase 1A: Cohort 8 Dose Escalation	Phase 1A: Cohort 9 Dose Escalation
Number of subjects	3	3	3
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years			
arithmetic mean	49.7	66.3	63.3
standard deviation	± 9.71	± 9.07	± 8.50
Gender categorical Units: Subjects			
Female	3	3	3
Male	0	0	0
Ethnicity Units: Subjects			
Not of Hispanic, Latino/a, or Spanish origin	2	3	1
Missing	0	0	0
Hispanic, Latino/a, or Spanish origin	1	0	2
Race Units: Subjects			
Asian	0	0	0
American Indian or Alaskan Native	0	0	0
Black or African American	1	0	0
Native Hawaiian and Pacific Islander	0	0	0
White	1	3	3
Other	1	0	0
Not reported	0	0	0
Multiple	0	0	0
Unknown	0	0	0

Reporting group values	Phase 1A: Cohort 10 Dose Escalation	Phase 1A: Cohort 11 Dose Escalation	Phase 1A: Cohort 12 Dose Escalation
Number of subjects	3	7	7

Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years arithmetic mean standard deviation	61.7 ± 3.51	60.7 ± 9.30	61.7 ± 14.95
Gender categorical Units: Subjects			
Female	1	2	4
Male	2	5	3
Ethnicity Units: Subjects			
Not of Hispanic, Latino/a, or Spanish origin	3	7	6
Missing	0	0	0
Hispanic, Latino/a, or Spanish origin	0	0	1
Race Units: Subjects			
Asian	0	0	2
American Indian or Alaskan Native	0	0	0
Black or African American	1	0	0
Native Hawaiian and Pacific Islander	0	0	0
White	2	6	5
Other	0	1	0
Not reported	0	0	0
Multiple	0	0	0
Unknown	0	0	0

<b>Reporting group values</b>	Phase 1B Dose Expansion	Phase 2: Cohort A	Phase 2: Cohort B
Number of subjects	20	32	15
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years			

85 years and over			
-------------------	--	--	--

Age continuous Units: years arithmetic mean standard deviation	60.3 ± 15.63	65.3 ± 9.92	66.8 ± 10.90
Gender categorical Units: Subjects			
Female	12	12	10
Male	8	20	5
Ethnicity Units: Subjects			
Not of Hispanic, Latino/a, or Spanish origin	19	30	12
Missing	0	0	0
Hispanic, Latino/a, or Spanish origin	1	2	3
Race Units: Subjects			
Asian	1	0	0
American Indian or Alaskan Native	0	0	0
Black or African American	2	0	1
Native Hawaiian and Pacific Islander	0	0	0
White	16	20	12
Other	1	0	1
Not reported	0	10	0
Multiple	0	0	1
Unknown	0	2	0

Reporting group values	Phase 2: Cohort C	Phase 2: Cohort D	Phase 2: Cohort E
Number of subjects	12	9	32
Age categorical Units: Subjects			
In utero			
Preterm newborn infants (gestational age < 37 wks)			
Newborns (0-27 days)			
Infants and toddlers (28 days-23 months)			
Children (2-11 years)			
Adolescents (12-17 years)			
Adults (18-64 years)			
From 65-84 years			
85 years and over			
Age continuous Units: years arithmetic mean standard deviation	56.7 ± 16.14	66.2 ± 4.60	63.7 ± 9.26
Gender categorical Units: Subjects			
Female	7	5	32
Male	5	4	0



Ethnicity			
Units: Subjects			
Not of Hispanic, Latino/a, or Spanish origin	8	8	25
Missing	1	0	3
Hispanic, Latino/a, or Spanish origin	3	1	4
Race			
Units: Subjects			
Asian	0	1	0
American Indian or Alaskan Native	0	0	0
Black or African American	0	0	0
Native Hawaiian and Pacific Islander	0	0	0
White	7	6	27
Other	0	0	0
Not reported	4	2	4
Multiple	0	0	0
Unknown	1	0	1

Reporting group values	Phase 2: Cohort F	Total	
Number of subjects	14	190	
Age categorical			
Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous			
Units: years			
arithmetic mean	65.6		
standard deviation	± 10.55	-	
Gender categorical			
Units: Subjects			
Female	6	121	
Male	8	69	
Ethnicity			
Units: Subjects			
Not of Hispanic, Latino/a, or Spanish origin	12	164	
Missing	0	4	
Hispanic, Latino/a, or Spanish origin	2	22	
Race			
Units: Subjects			
Asian	1	6	
American Indian or Alaskan Native	0	0	
Black or African American	0	8	
Native Hawaiian and Pacific Islander	0	0	

White	11	145	
Other	0	4	
Not reported	1	21	
Multiple	0	1	
Unknown	1	5	

## End points

### End points reporting groups

Reporting group title	Phase 1A: Cohort 1 Dose Escalation
Reporting group description: Subjects received ASTX029 10 milligrams (mg), powder in bottle (PiB), orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
Reporting group title	Phase 1A: Cohort 2 Dose Escalation
Reporting group description: Subjects received ASTX029 20 mg, PiB, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
Reporting group title	Phase 1A: Cohort 3 Dose Escalation
Reporting group description: Subjects received ASTX029 60 mg, PiB, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
Reporting group title	Phase 1A: Cohort 4 Dose Escalation
Reporting group description: Subjects received ASTX029 120 mg, PiB, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
Reporting group title	Phase 1A: Cohort 5 Dose Escalation
Reporting group description: Subjects received ASTX029 200 mg, orally, PiB, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
Reporting group title	Phase 1A: Cohort 6 Dose Escalation
Reporting group description: Subjects received ASTX029 80 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
Reporting group title	Phase 1A: Cohort 7 Dose Escalation
Reporting group description: Subjects received ASTX029 120 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
Reporting group title	Phase 1A: Cohort 8 Dose Escalation
Reporting group description: Subjects received ASTX029 40 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
Reporting group title	Phase 1A: Cohort 9 Dose Escalation
Reporting group description: Subjects received ASTX029 80 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
Reporting group title	Phase 1A: Cohort 10 Dose Escalation
Reporting group description: Subjects received ASTX029 120 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
Reporting group title	Phase 1A: Cohort 11 Dose Escalation
Reporting group description: Subjects received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
Reporting group title	Phase 1A: Cohort 12 Dose Escalation
Reporting group description: Subjects received ASTX029 280 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	
Reporting group title	Phase 1B Dose Expansion
Reporting group description: Subjects received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.	

Reporting group title	Phase 2: Cohort A
Reporting group description:	
Subjects with neuroblastoma RAS (NRAS)-mutant melanoma received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.	
Reporting group title	Phase 2: Cohort B
Reporting group description:	
Subjects with Kirsten RAS (KRAS)-mutant or KRAS-amplified non-small cell lung cancer (NSCLC) received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.	
Reporting group title	Phase 2: Cohort C
Reporting group description:	
Subjects with B isoform of RAF kinase (BRAF) V600-mutant cancers (non-colorectal cancers) received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.	
Reporting group title	Phase 2: Cohort D
Reporting group description:	
Subjects with BRAF-fusion cancers received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.	
Reporting group title	Phase 2: Cohort E
Reporting group description:	
Subjects with gynecological cancers with alterations in the mitogen-activated protein kinase (MAPK) pathway received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.	
Reporting group title	Phase 2: Cohort F
Reporting group description:	
Subjects with tumors that were characterized by other gene aberrations (that upregulate the MAPK signal pathway) received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.	
Subject analysis set title	Phase 1A: Cohort 10 Dose Escalation
Subject analysis set type	Full analysis
Subject analysis set description:	
Subjects received ASTX029 120 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
Subject analysis set title	Phase 1A: Cohort 11 Dose Escalation
Subject analysis set type	Full analysis
Subject analysis set description:	
Subjects received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.	
<b>Primary: Phase 1: Number of Subjects With Dose Limiting Toxicities (DLTs)</b>	
End point title	Phase 1: Number of Subjects With Dose Limiting Toxicities (DLTs) <sup>[1][2]</sup>
End point description:	
DLTs were defined as adverse events (AEs) graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03 criteria that occurred during the first cycle of treatment and represented any 1 of the following: grade 4 thrombocytopenia of any duration; ≥grade 3 hematologic toxicity with complications (e.g., grade 3 thrombocytopenia with bleeding or transfusion requirement); febrile neutropenia of any duration or grade 4 neutropenia of 5 days or more duration; liver-associated abnormalities; ≥grade 2 eye disorders; symptomatic grade 2 cutaneous toxicities (including skin rash); any other ≥grade 3 nonhematologic AE except grade 3 nausea, vomiting, or diarrhea; Any event that, in the opinion of the Data and Safety Review Committee (DSRC), would suggest that further dose escalation would put subjects at unacceptable risk. The safety analysis set included data from all subjects who received any amount of study drug.	
End point type	Primary
End point timeframe:	
Cycle 1 (cycle length = 21 days)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistics is provided for this end point.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 1A: Cohort 1 Dose Escalation	Phase 1A: Cohort 2 Dose Escalation	Phase 1A: Cohort 3 Dose Escalation	Phase 1A: Cohort 4 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	5
Units: count of subjects	0	0	0	0

End point values	Phase 1A: Cohort 5 Dose Escalation	Phase 1A: Cohort 6 Dose Escalation	Phase 1A: Cohort 7 Dose Escalation	Phase 1A: Cohort 8 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	6	3	3
Units: count of subjects	1	0	0	0

End point values	Phase 1A: Cohort 9 Dose Escalation	Phase 1A: Cohort 10 Dose Escalation	Phase 1A: Cohort 11 Dose Escalation	Phase 1A: Cohort 12 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	7	7
Units: count of subjects	0	0	0	1

End point values	Phase 1B Dose Expansion			
Subject group type	Reporting group			
Number of subjects analysed	20			
Units: count of subjects	0			

## Statistical analyses

No statistical analyses for this end point

## Primary: Phase 1: Number of Subjects with Treatment Emergent Adverse Events (TEAEs)

End point title	Phase 1: Number of Subjects with Treatment Emergent Adverse Events (TEAEs) <sup>[3][4]</sup>
-----------------	----------------------------------------------------------------------------------------------

End point description:

An AE is defined as any untoward medical occurrence associated with the use of a drug in humans,

whether or not considered drug related. TEAEs are defined as events that first occurred or worsened on or after the date of the first dose of study treatment until 30 days after the last dose of study treatment or until the start of a posttreatment alternative anti-cancer treatment, whichever occurs first, with the following exceptions: events that occurred after 30 days beyond the last dose of study treatment or the start of a posttreatment alternative anti-cancer treatment will also be considered treatment-emergent if the events are both serious and related to the study treatment. The safety analysis set included data from all subjects who received any amount of study drug.

End point type	Primary
----------------	---------

End point timeframe:

From first dose of study drug up to 30 days after last dose (Up to 74 months)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistics is provided for this end point.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 1A: Cohort 1 Dose Escalation	Phase 1A: Cohort 2 Dose Escalation	Phase 1A: Cohort 3 Dose Escalation	Phase 1A: Cohort 4 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	5
Units: count of subjects	3	3	3	5

End point values	Phase 1A: Cohort 5 Dose Escalation	Phase 1A: Cohort 6 Dose Escalation	Phase 1A: Cohort 7 Dose Escalation	Phase 1A: Cohort 8 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	6	3	3
Units: count of subjects	10	6	3	3

End point values	Phase 1A: Cohort 9 Dose Escalation	Phase 1A: Cohort 10 Dose Escalation	Phase 1A: Cohort 11 Dose Escalation	Phase 1A: Cohort 12 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	7	7
Units: count of subjects	3	3	7	7

End point values	Phase 1B Dose Expansion			
Subject group type	Reporting group			
Number of subjects analysed	20			
Units: count of subjects	20			

## Statistical analyses

No statistical analyses for this end point

### Primary: Phase 2: Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

End point title	Phase 2: Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 <sup>[5][6]</sup>
-----------------	------------------------------------------------------------------------------------------------------------------------------------

End point description:

The ORR was calculated as the number of evaluable subjects whose best response was complete response (CR) or partial response (PR), divided by the total number of subjects evaluable for ORR analysis. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to <10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Percentages were rounded off to the nearest single decimal place. The efficacy analysis set included all subjects who received any amount of study drug. The ORR analysis was based on subjects who were in the efficacy analysis set and who had disease assessment at baseline and at least 1 follow-up disease assessment or subjects who died or stopped treatment before the first scheduled disease assessment due to clinical progression or toxicity.

End point type	Primary
----------------	---------

End point timeframe:

Every 2 cycles for the first 4 cycles and then every 4 cycles thereafter until disease progression (Up to 74 months)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistics is provided for this end point.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 2: Cohort A	Phase 2: Cohort B	Phase 2: Cohort C	Phase 2: Cohort D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	32	15	12	9
Units: percentage of subjects				
number (confidence interval 90%)	12.5 (4.4 to 26.4)	0 (0 to 18.1)	8.3 (0.4 to 33.9)	0 (0 to 28.3)

End point values	Phase 2: Cohort E	Phase 2: Cohort F		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	14		
Units: percentage of subjects				
number (confidence interval 90%)	12.5 (4.4 to 26.4)	7.1 (0.4 to 29.7)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 1: Area Under the Concentration-time Curve From Time Zero to 24

## Hours (AUC0-24) of ASTX029

End point title	Phase 1: Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC0-24) of ASTX029 <sup>[7]</sup>
-----------------	-----------------------------------------------------------------------------------------------------------------

### End point description:

As per planned analysis, data for subjects from Part A (Dose Escalation) and Part B (Expansion) were combined for Cohort 11 (200 mg). The pharmacokinetics (PK) analysis set included all subjects who had received study drug with available plasma concentrations and PK parameters for ASTX029. Here, subjects analysed is the number of subjects with data available for analysis and 'n' represents unique number of subjects out of all the assessed subjects with data available at the specified timepoint. 2 subjects who received 200 and 280 mg respectively, in Cycle 1 Day1 (C1D1), received 120 mg in Cycle 2 and Day 1 (C2D1) and hence counted in Cohort 10. 1 subject who received 280 mg in C1D1, received 200 mg in C2D1 and hence counted in Cohort 11.

End point type	Secondary
----------------	-----------

### End point timeframe:

Pre-dose on Day 1 of Cycles 1 and 2 and at 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose on Day 1 of Cycles 1 and 2 (Cycle length = 21 days)

### Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 1A: Cohort 1 Dose Escalation	Phase 1A: Cohort 2 Dose Escalation	Phase 1A: Cohort 3 Dose Escalation	Phase 1A: Cohort 4 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	5
Units: hours*nanograms/millilitres (h*ng/mL)				
geometric mean (geometric coefficient of variation)				
C1D1 (n = 2,3,3,5,10,6,3,2,3,3,26,7)	277 (± 20.1)	361 (± 222.0)	1150 (± 10.0)	4020 (± 83.0)
C2D1 (n = 3,2,3,4,5,4,3,2,3,5,23,3)	339 (± 58.4)	618 (± 11.7)	1410 (± 61.4)	3530 (± 104.5)

End point values	Phase 1A: Cohort 5 Dose Escalation	Phase 1A: Cohort 6 Dose Escalation	Phase 1A: Cohort 7 Dose Escalation	Phase 1A: Cohort 8 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	6	3	2
Units: hours*nanograms/millilitres (h*ng/mL)				
geometric mean (geometric coefficient of variation)				
C1D1 (n = 2,3,3,5,10,6,3,2,3,3,26,7)	7250 (± 63.7)	1810 (± 126.9)	3360 (± 140.4)	3080 (± 128.2)
C2D1 (n = 3,2,3,4,5,4,3,2,3,5,23,3)	7550 (± 76.9)	2490 (± 108.4)	3710 (± 106.0)	3370 (± 117.8)

End point values	Phase 1A: Cohort 9 Dose Escalation	Phase 1A: Cohort 12 Dose Escalation	Phase 1A: Cohort 10 Dose Escalation	Phase 1A: Cohort 11 Dose Escalation
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	3	7	5	26
Units: hours*nanograms/millilitres (h*ng/mL)				
geometric mean (geometric coefficient				



of variation)				
C1D1 (n = 2,3,3,5,10,6,3,2,3,3,26,7)	6500 (± 64.3)	17800 (± 83.6)	5710 (± 27.1)	13400 (± 46.4)
C2D1 (n = 3,2,3,4,5,4,3,2,3,5,23,3)	6430 (± 71.6)	25600 (± 91.9)	7850 (± 37.1)	15400 (± 57.5)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 1: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC<sub>0-last</sub>) of ASTX029

End point title	Phase 1: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC <sub>0-last</sub> ) of ASTX029 <sup>[8]</sup>
-----------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

As per planned analysis, data for subjects from Part A (Dose Escalation) and Part B (Expansion) were combined for Cohort 11 (200 mg). The PK analysis set included all subjects who had received study drug with available plasma concentrations and PK parameters for ASTX029. Here, subjects analysed is the number of subjects with data available for analysis and 'n' represents unique number of subjects out of all the assessed subjects with data available at the specified timepoint. 2 subjects who received 200 and 280 mg respectively, in C1D1, received 120 mg in C2D1 and hence counted in Cohort 10. 1 subject who received 280 mg in C1D1, received 200 mg in C2D1 and hence counted in Cohort 11.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose on Day 1 of Cycles 1 and 2 and at 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose on Day 1 of Cycles 1 and 2 (Cycle length = 21 days)

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 1A: Cohort 1 Dose Escalation	Phase 1A: Cohort 2 Dose Escalation	Phase 1A: Cohort 3 Dose Escalation	Phase 1A: Cohort 4 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	5
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)				
C1D1 (n = 3,3,3,5,10,6,3,3,3,3,27,7)	262 (± 18.5)	347 (± 215.6)	1140 (± 10.0)	4020 (± 82.9)
C2D1 (n = 3,3,3,4,5,4,3,2,3,5,25,3)	321 (± 56.1)	298 (± 177.3)	1410 (± 61.5)	3530 (± 104.5)

End point values	Phase 1A: Cohort 5 Dose Escalation	Phase 1A: Cohort 6 Dose Escalation	Phase 1A: Cohort 7 Dose Escalation	Phase 1A: Cohort 8 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	6	3	3
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)				
C1D1 (n = 3,3,3,5,10,6,3,3,3,3,27,7)	7250 (± 63.7)	1740 (± 137.5)	3360 (± 140.4)	1620 (± 215.6)
C2D1 (n = 3,3,3,4,5,4,3,2,3,5,25,3)	7530 (± 77.2)	2430 (± 116.3)	3660 (± 104.2)	3340 (± 116.4)

End point values	Phase 1A: Cohort 9 Dose Escalation	Phase 1A: Cohort 12 Dose Escalation	Phase 1A: Cohort 10 Dose Escalation	Phase 1A: Cohort 11 Dose Escalation
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	3	7	5	27
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)				
C1D1 (n = 3,3,3,5,10,6,3,3,3,27,7)	6450 (± 65.8)	17800 (± 83.6)	5710 (± 26.9)	12800 (± 51.2)
C2D1 (n = 3,3,3,4,5,4,3,2,3,5,25,3)	6450 (± 72.0)	25300 (± 93.7)	7850 (± 37.1)	13500 (± 80.0)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 1: Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of ASTX029

End point title	Phase 1: Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of ASTX029 <sup>[9]</sup>
-----------------	-------------------------------------------------------------------------------------------------------------------------------

End point description:

As per planned analysis, data for subjects from Part A (Dose Escalation) and Part B (Expansion) were combined for Cohort 11 (200 mg). The PK analysis set included all subjects who had received study drug with available plasma concentrations and PK parameters for ASTX029. Here, subjects analysed is the number of subjects with data available for analysis and 'n' represents unique number of subjects out of all the assessed subjects with data available at the specified timepoint. 2 subjects who received 200 and 280 mg respectively, in C1D1, received 120 mg in C2D1 and hence counted in Cohort 10. 1 subject who received 280 mg in C1D1, received 200 mg in C2D1 and hence counted in Cohort 11.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose on Day 1 of Cycles 1 and 2 and at 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose on Day 1 of Cycles 1 and 2 (Cycle length = 21 days)

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 1A: Cohort 1 Dose Escalation	Phase 1A: Cohort 2 Dose Escalation	Phase 1A: Cohort 3 Dose Escalation	Phase 1A: Cohort 4 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	5
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)				
C1D1 (n= 2,3,2,5,9,4,3,2,3,3,25,7)	327 (± 3.6)	358 (± 209.2)	1150 (± 14.1)	4050 (± 82.5)
C2D1 (n= 3,2,3,3,5,4,2,2,2,5,25,3)	346 (± 52.9)	243 (± 228.9)	1430 (± 60.9)	5160 (± 55.0)

End point values	Phase 1A: Cohort 5 Dose Escalation	Phase 1A: Cohort 6 Dose Escalation	Phase 1A: Cohort 7 Dose Escalation	Phase 1A: Cohort 8 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	4	3	2
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)				
C1D1 (n= 2,3,2,5,9,4,3,2,3,3,25,7)	8170 (± 53.5)	1180 (± 112.9)	3390 (± 139.3)	3120 (± 126.3)
C2D1 (n= 3,2,3,3,5,4,2,2,2,5,25,3)	7670 (± 75.3)	2470 (± 116.1)	3190 (± 169.8)	3420 (± 113.6)

End point values	Phase 1A: Cohort 9 Dose Escalation	Phase 1A: Cohort 12 Dose Escalation	Phase 1A: Cohort 10 Dose Escalation	Phase 1A: Cohort 11 Dose Escalation
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	3	7	5	25
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)				
C1D1 (n= 2,3,2,5,9,4,3,2,3,3,25,7)	6520 (± 66.6)	17900 (± 83.1)	5770 (± 26.7)	13500 (± 47.1)
C2D1 (n= 3,2,3,3,5,4,2,2,2,5,25,3)	5590 (± 101.3)	25600 (± 92.2)	7930 (± 37.2)	15700 (± 59.0)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 1: Maximum Observed Plasma Concentration (Cmax) of ASTX029

End point title	Phase 1: Maximum Observed Plasma Concentration (Cmax) of ASTX029 <sup>[10]</sup>
-----------------	----------------------------------------------------------------------------------

End point description:

As per planned analysis, data for subjects from Part A (Dose Escalation) and Part B (Expansion) were combined for Cohort 11 (200 mg). The PK analysis set included all subjects who had received study drug with available plasma concentrations and PK parameters for ASTX029. Here, subjects analysed is the number of subjects with data available for analysis and 'n' represents unique number of subjects out of all the assessed subjects with data available at the specified timepoint. 2 subjects who received 200 and 280 mg respectively, in C1D1, received 120 mg in C2D1 and hence counted in Cohort 10. 1 subject who received 280 mg in C1D1, received 200 mg in C2D1 and hence counted in Cohort 11.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose on Day 1 of Cycles 1 and 2 and at 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose on Day 1 of Cycles 1 and 2 (Cycle length = 21 days)

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 1A: Cohort 1 Dose Escalation	Phase 1A: Cohort 2 Dose Escalation	Phase 1A: Cohort 3 Dose Escalation	Phase 1A: Cohort 4 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	5
Units: nanograms/millilitre (ng/mL)				
geometric mean (geometric coefficient of variation)				
C1D1 (n= 3,3,3,5,10,6,3,3,3,5,27,7)	109 (± 48.5)	217 (± 165.4)	469 (± 9.5)	1650 (± 56.8)
C2D1 (n= 3,3,3,4,5,4,3,2,3,5,25,3)	143 (± 177.8)	107 (± 119.2)	598 (± 111.0)	903 (± 228.8)

End point values	Phase 1A: Cohort 5 Dose Escalation	Phase 1A: Cohort 6 Dose Escalation	Phase 1A: Cohort 7 Dose Escalation	Phase 1A: Cohort 8 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	6	3	3
Units: nanograms/millilitre (ng/mL)				
geometric mean (geometric coefficient of variation)				
C1D1 (n= 3,3,3,5,10,6,3,3,3,5,27,7)	1850 (± 66.7)	496 (± 127.7)	1490 (± 141.7)	742 (± 301.5)
C2D1 (n= 3,3,3,4,5,4,3,2,3,5,25,3)	1830 (± 177.6)	641 (± 91.4)	1710 (± 124.4)	2330 (± 130.8)

End point values	Phase 1A: Cohort 9 Dose Escalation	Phase 1A: Cohort 12 Dose Escalation	Phase 1A: Cohort 10 Dose Escalation	Phase 1A: Cohort 11 Dose Escalation
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	3	7	5	27
Units: nanograms/millilitre (ng/mL)				
geometric mean (geometric coefficient of variation)				
C1D1 (n= 3,3,3,5,10,6,3,3,3,5,27,7)	2840 (± 30.8)	6040 (± 58.4)	2060 (± 49.5)	5240 (± 61.0)
C2D1 (n= 3,3,3,4,5,4,3,2,3,5,25,3)	1860 (± 55.8)	8070 (± 50.7)	2360 (± 40.9)	5350 (± 78.7)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 1: Minimum Plasma Concentration (Cmin) of ASTX029

End point title	Phase 1: Minimum Plasma Concentration (Cmin) of ASTX029 <sup>[11]</sup>
-----------------	-------------------------------------------------------------------------

End point description:

As per planned analysis, data for subjects from Part A (Dose Escalation) and Part B (Expansion) were combined for Cohort 11 (200 mg). The PK analysis set included all subjects who had received study drug with available plasma concentrations and PK parameters for ASTX029. Here, subjects analysed is the number of subjects with data available for analysis. 2 subjects who received 200 and 280 mg respectively, in C1D1, received 120 mg in C2D1 and hence counted in Cohort 10. 1 subject who received 280 mg in C1D1, received 200 mg in C2D1 and hence counted in Cohort 11. Data for Cmin was calculated and analysed for C2D1 only.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose and at 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose on Day 1 of Cycle 2 (Cycle length = 21 days)

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 1A: Cohort 1 Dose Escalation	Phase 1A: Cohort 2 Dose Escalation	Phase 1A: Cohort 3 Dose Escalation	Phase 1A: Cohort 4 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	4
Units: ng/mL				
geometric mean (geometric coefficient of variation)	4.38 (± 86.7)	1.45 (± 173.2)	23.4 (± 127.8)	19.3 (± 149.7)

End point values	Phase 1A: Cohort 5 Dose Escalation	Phase 1A: Cohort 6 Dose Escalation	Phase 1A: Cohort 7 Dose Escalation	Phase 1A: Cohort 8 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	4	3	2
Units: ng/mL				
geometric mean (geometric coefficient of variation)	18.1 (± 39.7)	7.88 (± 79.3)	68.1 (± 128.8)	8.68 (± 64.0)

End point values	Phase 1A: Cohort 9 Dose Escalation	Phase 1A: Cohort 12 Dose Escalation	Phase 1A: Cohort 10 Dose Escalation	Phase 1A: Cohort 11 Dose Escalation
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	3	3	5	25
Units: ng/mL				
geometric mean (geometric coefficient of variation)	20.1 (± 114.7)	168 (± 85.6)	85.3 (± 206.9)	188 (± 194.3)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 1: Time to Reach Maximum Concentration (Tmax) of ASTX029

End point title	Phase 1: Time to Reach Maximum Concentration (Tmax) of ASTX029 <sup>[12]</sup>
-----------------	--------------------------------------------------------------------------------

End point description:

As per planned analysis, data for subjects from Part A (Dose Escalation) and Part B (Expansion) were combined for Cohort 11 (200 mg). The PK analysis set included all subjects who had received study drug with available plasma concentrations and PK parameters for ASTX029. Here, subjects analysed is the number of subjects with data available for analysis and 'n' represents unique number of subjects out of all the assessed subjects with data available at the specified timepoint. 2 subjects who received 200 and 280 mg respectively, in C1D1, received 120 mg in C2D1 and hence counted in Cohort 10. 1 subject who

received 280 mg in C1D1, received 200 mg in C2D1 and hence counted in Cohort 11.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose on Day 1 of Cycles 1 and 2 and at 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose on Day 1 of Cycles 1 and 2 (Cycle length = 21 days)

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 1A: Cohort 1 Dose Escalation	Phase 1A: Cohort 2 Dose Escalation	Phase 1A: Cohort 3 Dose Escalation	Phase 1A: Cohort 4 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	5
Units: hours				
median (full range (min-max))				
C1D1 (n= 3,3,3,5,10,6,3,3,3,27,7)	1.08 (0.57 to 3.05)	0.50 (0.50 to 0.58)	0.55 (0.47 to 0.97)	0.50 (0.50 to 1.00)
C2D1 (n= 3,3,3,4,5,4,3,2,3,5,25,3)	0.53 (0.50 to 2.20)	1.00 (0.55 to 1.05)	0.50 (0.47 to 0.92)	2.52 (0.92 to 5.7)

End point values	Phase 1A: Cohort 5 Dose Escalation	Phase 1A: Cohort 6 Dose Escalation	Phase 1A: Cohort 7 Dose Escalation	Phase 1A: Cohort 8 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	6	3	3
Units: hours				
median (full range (min-max))				
C1D1 (n= 3,3,3,5,10,6,3,3,3,27,7)	0.71 (0.43 to 4.08)	3.03 (1.08 to 5.73)	1.00 (0.98 to 3.00)	1.07 (1.00 to 4.02)
C2D1 (n= 3,3,3,4,5,4,3,2,3,5,25,3)	0.55 (0.50 to 1.00)	2.48 (0.52 to 3.85)	1.02 (0.50 to 7.53)	1.52 (1.00 to 2.03)

End point values	Phase 1A: Cohort 9 Dose Escalation	Phase 1A: Cohort 12 Dose Escalation	Phase 1A: Cohort 10 Dose Escalation	Phase 1A: Cohort 11 Dose Escalation
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	3	7	5	27
Units: hours				
median (full range (min-max))				
C1D1 (n= 3,3,3,5,10,6,3,3,3,27,7)	1.00 (0.47 to 1.88)	2.03 (1.00 to 4.00)	1.88 (0.53 to 1.93)	1.97 (0.50 to 6.00)
C2D1 (n= 3,3,3,4,5,4,3,2,3,5,25,3)	3.00 (2.93 to 5.67)	1.90 (0.55 to 3.85)	2.1 (1.08 to 4)	2.02 (0.92 to 7.52)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 1: Elimination Half-Life (T1/2) of ASTX029

End point title	Phase 1: Elimination Half-Life (T1/2) of ASTX029 <sup>[13]</sup>
-----------------	------------------------------------------------------------------

End point description:

As per planned analysis, data for subjects from Part A (Dose Escalation) and Part B (Expansion) were combined for Cohort 11 (200 mg). The PK analysis set included all subjects who had received study drug with available plasma concentrations and PK parameters for ASTX029. Here, subjects analysed is the number of subjects with data available for analysis and 'n' represents unique number of subjects out of all the assessed subjects with data available at the specified timepoint. 2 subjects who received 200 and 280 mg respectively, in C1D1, received 120 mg in C2D1 and hence counted in Cohort 10. 1 subject who received 280 mg in C1D1, received 200 mg in C2D1 and hence counted in Cohort 11.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose on Day 1 of Cycles 1 and 2 and at 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose on Day 1 of Cycles 1 and 2 (Cycle length = 21 days)

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 1A: Cohort 1 Dose Escalation	Phase 1A: Cohort 2 Dose Escalation	Phase 1A: Cohort 3 Dose Escalation	Phase 1A: Cohort 4 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	5
Units: hours				
geometric mean (geometric coefficient of variation)				
C1D1 (n= 2,3,2,5,9,4,3,2,3,3,25,7)	2.42 (± 42.1)	1.63 (± 18.7)	4.42 (± 1.8)	3.75 (± 26.9)
C2D1 (n= 3,2,3,3,5,4,2,2,2,5,21,3)	3.37 (± 119.7)	1.85 (± 64.8)	4.98 (± 31.5)	3.61 (± 13.5)

End point values	Phase 1A: Cohort 5 Dose Escalation	Phase 1A: Cohort 6 Dose Escalation	Phase 1A: Cohort 7 Dose Escalation	Phase 1A: Cohort 8 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	4	3	2
Units: hours				
geometric mean (geometric coefficient of variation)				
C1D1 (n= 2,3,2,5,9,4,3,2,3,3,25,7)	3.84 (± 21.8)	2.08 (± 102.4)	4.28 (± 11.6)	5.68 (± 31.7)
C2D1 (n= 3,2,3,3,5,4,2,2,2,5,21,3)	4.11 (± 15.9)	2.58 (± 95.1)	1.01 (± 11.6)	3.13 (± 276.4)

End point values	Phase 1A: Cohort 9 Dose Escalation	Phase 1A: Cohort 12 Dose Escalation	Phase 1A: Cohort 10 Dose Escalation	Phase 1A: Cohort 11 Dose Escalation
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	3	7	5	25

Units: hours				
geometric mean (geometric coefficient of variation)				
C1D1 (n= 2,3,2,5,9,4,3,2,3,3,25,7)	3.30 (± 74.7)	3.71 (± 32.9)	4.00 (± 13.6)	3.92 (± 40.9)
C2D1 (n= 3,2,3,3,5,4,2,2,2,5,21,3)	4.67 (± 24.1)	1.28 (± 72.1)	3.88 (± 25.6)	3.80 (± 47.2)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 1: Effect of Food on AUC0-24 of ASTX029

End point title	Phase 1: Effect of Food on AUC0-24 of ASTX029 <sup>[14]</sup>
-----------------	---------------------------------------------------------------

End point description:

The food effect was to be analysed only for tablet dosage forms. The subjects who were administered 80 mg and 120 mg tablets, under both fed and fasted conditions were reported. As 200 mg dose was administered, as tablets, only under fasted conditions, hence food effect was not assessed for 200 mg dose. The statistical comparison between fed and fasted state treatment arm groups of 80 mg and 120 mg doses is reported in this end point for food effect. The data is reported here for the arm groups of 80 mg and 120 mg, in both fed and fasted to compare food effect. Here, subjects analysed is the number of subjects with data available for analysis and 'n' represents unique number of subjects out of all the assessed subjects with data available at the specified timepoint. The 2 subjects who received 200 and 280 mg respectively, in C1D1, received 120 mg in C2D1 and hence counted in Cohort 10.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose on Day 1 of Cycles 1 and 2 and at 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose on Day 1 of Cycles 1 and 2 (Cycle length = 21 days)

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The statistical analysis was planned only between fed and fasted state treatment arm groups of 80 mg and 120 mg doses is reported in this end point or food effect for this endpoint.

End point values	Phase 1A: Cohort 6 Dose Escalation	Phase 1A: Cohort 7 Dose Escalation	Phase 1A: Cohort 9 Dose Escalation	Phase 1A: Cohort 10 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	6	3	3	5
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)				
C1D1 (n= 6,3,3,3)	1810 (± 126.9)	3360 (± 140.4)	6500 (± 64.3)	5710 (± 27.1)
C2D1 (n= 4,3,3,5)	2490 (± 108.4)	3710 (± 106.0)	6430 (± 71.6)	7850 (± 37.1)

## Statistical analyses

Statistical analysis title	Comparison of Cohorts 6 and 9 (80 mg) in C1D1
----------------------------	-----------------------------------------------

Statistical analysis description:

Comparison of effect of food on AUC0-24 between Cohort 6 (fed state) and Cohort 9 (fasted state) treatment arm groups of 80 mg ASTX029 in C1D1.

Comparison groups	Phase 1A: Cohort 6 Dose Escalation v Phase 1A: Cohort 9 Dose Escalation
-------------------	-------------------------------------------------------------------------



Number of subjects included in analysis	9
Analysis specification	Pre-specified
Analysis type	superiority <sup>[15]</sup>
Parameter estimate	Geo LSM Ratio
Point estimate	27.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	8.5
upper limit	91.2

Notes:

[15] - Geometric Least Squares Mean Ratio (Geo LSM Ratio) was calculated for Cohort 6 (fed state) and Cohort 9 (fasted state) treatment arm groups of 80 mg ASTX029.

<b>Statistical analysis title</b>	Comparison of Cohorts 6 and 9 (80 mg) in C2D1
-----------------------------------	-----------------------------------------------

Statistical analysis description:

Comparison of effect of food on AUC<sub>0-24</sub> between Cohort 6 (fed state) and Cohort 9 (fasted state) treatment arm groups of 80 mg ASTX029 in C2D1.

Comparison groups	Phase 1A: Cohort 6 Dose Escalation v Phase 1A: Cohort 9 Dose Escalation
Number of subjects included in analysis	9
Analysis specification	Pre-specified
Analysis type	superiority <sup>[16]</sup>
Parameter estimate	Geo LSM Ratio
Point estimate	38.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	11.4
upper limit	132

Notes:

[16] - Geo LSM ratio was calculated for Cohort 6 (fed state) and Cohort 9 (fasted state) treatment arm groups of 80 mg ASTX029.

<b>Statistical analysis title</b>	Comparison of Cohorts 7 and 10 (120 mg) in C1D1
-----------------------------------	-------------------------------------------------

Statistical analysis description:

Comparison of effect of food on AUC<sub>0-24</sub> between Cohort 7 (fed state) and Cohort 10 (fasted state) treatment arm groups of 120 mg ASTX029 in C1D1.

Comparison groups	Phase 1A: Cohort 7 Dose Escalation v Phase 1A: Cohort 10 Dose Escalation
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	superiority <sup>[17]</sup>
Parameter estimate	Geo LSM Ratio
Point estimate	58.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	15.7
upper limit	222

Notes:

[17] - Geo LSM ratio was calculated for Cohort 7 (fed state) and Cohort 10 (fasted state) treatment arm groups of 120 mg ASTX029.

<b>Statistical analysis title</b>	Comparison of Cohorts 7 and 10 (120 mg) in C2D1
-----------------------------------	-------------------------------------------------

Statistical analysis description:

Comparison of effect of food on AUC<sub>0-24</sub> between Cohort 7 (fed state) and Cohort 10 (fasted state) treatment arm groups of 120 mg ASTX029 in C2D1.

Comparison groups	Phase 1A: Cohort 7 Dose Escalation v Phase 1A: Cohort 10 Dose Escalation
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	superiority <sup>[18]</sup>
Parameter estimate	Geo LSM Ratio
Point estimate	47.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	20.7
upper limit	108

Notes:

[18] - Geo LSM ratio was calculated for Cohort 7 (fed state) and Cohort 10 (fasted state) treatment arm groups of 120 mg ASTX029.

## Secondary: Phase 1: Effect of Food on AUC<sub>0-inf</sub> of ASTX029

End point title	Phase 1: Effect of Food on AUC <sub>0-inf</sub> of ASTX029 <sup>[19]</sup>
-----------------	----------------------------------------------------------------------------

End point description:

The food effect was to be analysed only for tablet dosage forms. The subjects who were administered 80 mg and 120 mg tablets, under both fed and fasted conditions were reported. As 200 mg dose was administered, as tablets, only under fasted conditions, hence food effect was not assessed for 200 mg dose. The statistical comparison between fed and fasted state treatment arm groups of 80 mg and 120 mg doses is reported in this end point for food effect. The data is reported here for the arm groups of 80 mg and 120 mg, in both fed and fasted to compare food effect. Here, subjects analysed is the number of subjects with data available for analysis and 'n' represents unique number of subjects out of all the assessed subjects with data available at the specified timepoint. The 2 subjects who received 200 and 280 mg respectively, in C1D1, received 120 mg in C2D1 and hence counted in Cohort 10.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose on Day 1 of Cycles 1 and 2 and at 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose on Day 1 of Cycles 1 and 2 (Cycle length = 21 days)

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The statistical analysis was planned only between fed and fasted state treatment arm groups of 80 mg and 120 mg doses is reported in this end point for food effect for this endpoint.

End point values	Phase 1A: Cohort 6 Dose Escalation	Phase 1A: Cohort 7 Dose Escalation	Phase 1A: Cohort 9 Dose Escalation	Phase 1A: Cohort 10 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	4	3	3	5
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)				
C1D1 (n= 4,3,3,3)	1180 (± 112.9)	3390 (± 139.3)	6520 (± 66.6)	5770 (± 26.7)

C2D1 (n= 4,2,2,5)	2470 ( $\pm$ 116.1)	3190 ( $\pm$ 169.8)	5590 ( $\pm$ 101.3)	7930 ( $\pm$ 37.2)
-------------------	---------------------	---------------------	---------------------	--------------------

## Statistical analyses

<b>Statistical analysis title</b>	Comparison of Cohorts 6 and 9 (80 mg) in C1D1
-----------------------------------	-----------------------------------------------

Statistical analysis description:

Comparison of effect of food on AUC<sub>0-inf</sub> between Cohort 6 (fed state) and Cohort 9 (fasted state) treatment arm groups of 80 mg ASTX029 in C1D1.

Comparison groups	Phase 1A: Cohort 6 Dose Escalation v Phase 1A: Cohort 9 Dose Escalation
Number of subjects included in analysis	7
Analysis specification	Pre-specified
Analysis type	superiority <sup>[20]</sup>
Parameter estimate	Geo LSM Ratio
Point estimate	18.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	5.28
upper limit	61.9

Notes:

[20] - Geo LSM ratio was calculated for Cohort 6 (fed state) and Cohort 9 (fasted state) treatment arm groups of 80 mg ASTX029.

<b>Statistical analysis title</b>	Comparison of Cohorts 6 and 9 (80 mg) in C2D1
-----------------------------------	-----------------------------------------------

Statistical analysis description:

Comparison of effect of food on AUC<sub>0-inf</sub> between Cohort 6 (fed state) and Cohort 9 (fasted state) treatment arm groups of 80 mg ASTX029 in C2D1.

Comparison groups	Phase 1A: Cohort 6 Dose Escalation v Phase 1A: Cohort 9 Dose Escalation
Number of subjects included in analysis	7
Analysis specification	Pre-specified
Analysis type	superiority <sup>[21]</sup>
Parameter estimate	Geo LSM Ratio
Point estimate	44.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	8.32
upper limit	234

Notes:

[21] - Geo LSM ratio was calculated for Cohort 6 (fed state) and Cohort 9 (fasted state) treatment arm groups of 80 mg ASTX029.

<b>Statistical analysis title</b>	Comparison of Cohort 7 and 10 (120 mg) in C1D1
-----------------------------------	------------------------------------------------

Statistical analysis description:

Comparison of effect of food on AUC<sub>0-inf</sub> between Cohort 7 (fed state) and Cohort 10 (fasted state)

treatment arm groups of 120 mg ASTX029 in C1D1.

Comparison groups	Phase 1A: Cohort 7 Dose Escalation v Phase 1A: Cohort 10 Dose Escalation
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	superiority <sup>[22]</sup>
Parameter estimate	Geo LSM Ratio
Point estimate	58.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	15.7
upper limit	220

Notes:

[22] - Geo LSM ratio was calculated for Cohort 7 (fed state) and Cohort 10 (fasted state) treatment arm groups of 120 mg ASTX029.

<b>Statistical analysis title</b>	Comparison of Cohorts 7 and 10 (120 mg) in C2D1
-----------------------------------	-------------------------------------------------

Statistical analysis description:

Comparison of effect of food on AUC<sub>0</sub>-inf between Cohort 7 (fed state) and Cohort 10 (fasted state) treatment arm groups of 120 mg ASTX029 in C2D1.

Comparison groups	Phase 1A: Cohort 7 Dose Escalation v Phase 1A: Cohort 10 Dose Escalation
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	superiority <sup>[23]</sup>
Parameter estimate	Geo LSM Ratio
Point estimate	40.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	14.3
upper limit	113

Notes:

[23] - Geo LSM ratio was calculated for Cohort 7 (fed state) and Cohort 10 (fasted state) treatment arm groups of 120 mg ASTX029.

## Secondary: Phase 1: Effect of Food on C<sub>max</sub> of ASTX029

End point title	Phase 1: Effect of Food on C <sub>max</sub> of ASTX029 <sup>[24]</sup>
-----------------	------------------------------------------------------------------------

End point description:

The food effect was to be analysed only for tablet dosage forms. The subjects who were administered 80 mg and 120 mg tablets, under both fed and fasted conditions were reported. As 200 mg dose was administered, as tablets, only under fasted conditions, hence food effect was not assessed for 200 mg dose. The statistical comparison between fed and fasted state treatment arm groups of 80 mg and 120 mg doses is reported in this end point for food effect. The data is reported here for the arm groups of 80 mg and 120 mg, in both fed and fasted to compare food effect. Here, subjects analysed is the number of subjects with data available for analysis and 'n' represents unique number of subjects out of all the assessed subjects with data available at the specified timepoint. The 2 subjects who received 200 and 280 mg respectively, in C1D1, received 120 mg in C2D1 and hence counted in Cohort 10.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose on Day 1 of Cycles 1 and 2 and at 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose on Day 1 of Cycles 1 and 2 (Cycle length = 21 days)

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The statistical analysis was planned only between fed and fasted state treatment arm groups of 80 mg and 120 mg doses is reported in this end point for food effect for this endpoint.

End point values	Phase 1A: Cohort 6 Dose Escalation	Phase 1A: Cohort 7 Dose Escalation	Phase 1A: Cohort 9 Dose Escalation	Phase 1A: Cohort 10 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	6	3	3	5
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
C1D1 (n= 6,3,3,3)	496 (± 127.7)	1490 (± 141.7)	2840 (± 30.8)	2060 (± 49.5)
C2D1 (n= 4,3,3,5)	641 (± 91.4)	1710 (± 124.4)	1860 (± 55.8)	2360 (± 40.9)

## Statistical analyses

Statistical analysis title	Comparison of Cohorts 6 and 9 (80 mg) in C1D1
Statistical analysis description: Comparison of effect of food on Cmax between Cohort 6 (fed state) and Cohort 9 (fasted state) treatment arm groups of 80 mg ASTX029 in C1D1.	
Comparison groups	Phase 1A: Cohort 6 Dose Escalation v Phase 1A: Cohort 9 Dose Escalation
Number of subjects included in analysis	9
Analysis specification	Pre-specified
Analysis type	superiority <sup>[25]</sup>
Parameter estimate	Geo LSM Ratio
Point estimate	17.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	5.62
upper limit	54.3

Notes:

[25] - Geo LSM ratio was calculated for Cohort 6 (fed state) and Cohort 9 (fasted state) treatment arm groups of 80 mg ASTX029.

Statistical analysis title	Comparison of Cohorts 6 and 9 (80 mg) in C2D1
Statistical analysis description: Comparison of effect of food on Cmax between Cohort 6 (fed state) and Cohort 9 (fasted state) treatment arm groups of 80 mg ASTX029 in C2D1.	
Comparison groups	Phase 1A: Cohort 6 Dose Escalation v Phase 1A: Cohort 9 Dose Escalation

Number of subjects included in analysis	9
Analysis specification	Pre-specified
Analysis type	superiority <sup>[26]</sup>
Parameter estimate	Geo LSM Ratio
Point estimate	34.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	12
upper limit	99.4

Notes:

[26] - Geo LSM ratio was calculated for Cohort 6 (fed state) and Cohort 9 (fasted state) treatment arm groups of 80 mg ASTX029.

<b>Statistical analysis title</b>	Comparison of Cohorts 7 and 10 (120 mg) in C1D1
-----------------------------------	-------------------------------------------------

Statistical analysis description:

Comparison of effect of food on Cmax between Cohort 7 (fed state) and Cohort 10 (fasted state) treatment arm groups of 120 mg ASTX029 in C1D1.

Comparison groups	Phase 1A: Cohort 7 Dose Escalation v Phase 1A: Cohort 10 Dose Escalation
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	superiority <sup>[27]</sup>
Parameter estimate	Geo LSM Ratio
Point estimate	72.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	17.6
upper limit	299

Notes:

[27] - Geo LSM ratio was calculated for Cohort 7 (fed state) and Cohort 10 (fasted state) treatment arm groups of 120 mg ASTX029.

<b>Statistical analysis title</b>	Comparison of Cohorts 7 and 10 (120 mg) in C2D1
-----------------------------------	-------------------------------------------------

Statistical analysis description:

Comparison of effect of food on Cmax between Cohort 7 (fed state) and Cohort 10 (fasted state) treatment arm groups of 120 mg ASTX029 in C2D1.

Comparison groups	Phase 1A: Cohort 7 Dose Escalation v Phase 1A: Cohort 10 Dose Escalation
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	superiority <sup>[28]</sup>
Parameter estimate	Geo LSM Ratio
Point estimate	72.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	29.1
upper limit	181

Notes:

[28] - Geo LSM ratio was calculated for Cohort 7 (fed state) and Cohort 10 (fasted state) treatment arm groups of 120 mg ASTX029.

## Secondary: Phase 1: Effect of Food on Tmax of ASTX029

End point title	Phase 1: Effect of Food on Tmax of ASTX029 <sup>[29]</sup>
-----------------	------------------------------------------------------------

End point description:

The food effect was to be analysed only for tablet dosage forms. The subjects who were administered 80 mg and 120 mg tablets, under both fed and fasted conditions were reported. As 200 mg dose was administered, as tablets, only under fasted conditions, hence food effect was not assessed for 200 mg dose. The statistical comparison between fed and fasted state treatment arm groups of 80 mg and 120 mg doses is reported in this end point for food effect. The data is reported here for the arm groups of 80 mg and 120 mg, in both fed and fasted to compare food effect. Here, subjects analysed is the number of subjects with data available for analysis and 'n' represents unique number of subjects out of all the assessed subjects with data available at the specified timepoint. The 2 subjects who received 200 and 280 mg respectively, in C1D1, received 120 mg in C2D1 and hence counted in Cohort 10.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose on Day 1 of Cycles 1 and 2 and at 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose on Day 1 of Cycles 1 and 2 (Cycle length = 21 days)

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The statistical analysis was planned only between fed and fasted state treatment arm groups of 80 mg and 120 mg doses is reported in this end point for food effect for this endpoint.

End point values	Phase 1A: Cohort 6 Dose Escalation	Phase 1A: Cohort 7 Dose Escalation	Phase 1A: Cohort 9 Dose Escalation	Phase 1A: Cohort 10 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	6	3	3	5
Units: hours				
median (full range (min-max))				
C1D1 (n= 6,3,3,3)	3.03 (1.08 to 5.73)	1.00 (0.98 to 3.00)	1.00 (0.47 to 1.88)	1.88 (0.53 to 1.93)
C2D1 (n= 4,3,3,5)	2.48 (0.52 to 3.85)	1.02 (0.50 to 7.53)	3.00 (2.93 to 5.67)	2.1 (1.08 to 4)

## Statistical analyses

Statistical analysis title	Comparison of Cohorts 6 and 9 (80 mg) in C1D1
----------------------------	-----------------------------------------------

Statistical analysis description:

Comparison of effect of food on Tmax between Cohort 6 (fed state) and Cohort 9 (fasted state) treatment arm groups of 80 mg ASTX029 in C1D1.

Comparison groups	Phase 1A: Cohort 9 Dose Escalation v Phase 1A: Cohort 6 Dose Escalation
Number of subjects included in analysis	9
Analysis specification	Pre-specified
Analysis type	superiority <sup>[30]</sup>
P-value	= 0.038867
Method	Wilcoxon (Mann-Whitney)
Parameter estimate	Hodges-Lehmann Estimator
Point estimate	-2.275

Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.216
upper limit	0.083

Notes:

[30] - The Hodges-Lehmann estimator and 90% confidence interval (CI) was calculated using the Moses approximation.

<b>Statistical analysis title</b>	Comparison of Cohorts 6 and 9 (80 mg) in C2D1
-----------------------------------	-----------------------------------------------

Statistical analysis description:

Comparison of effect of food on Tmax between Cohort 6 (fed state) and Cohort 9 (fasted state) treatment arm groups of 80 mg ASTX029 in C2D1.

Comparison groups	Phase 1A: Cohort 6 Dose Escalation v Phase 1A: Cohort 9 Dose Escalation
Number of subjects included in analysis	9
Analysis specification	Pre-specified
Analysis type	superiority <sup>[31]</sup>
P-value	= 0.4795
Method	Wilcoxon (Mann-Whitney)
Parameter estimate	Hodges-Lehmann Estimator
Point estimate	1.45
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.917
upper limit	5.15

Notes:

[31] - The Hodges-Lehmann estimator and 90% CI was calculated using the Moses approximation.

<b>Statistical analysis title</b>	Comparison of Cohorts 7 and 10 (120 mg) in C1D1
-----------------------------------	-------------------------------------------------

Statistical analysis description:

Comparison of effect of food on Tmax between Cohort 7 (fed state) and Cohort 10 (fasted state) treatment arm groups of 120 mg ASTX029 in C1D1.

Comparison groups	Phase 1A: Cohort 7 Dose Escalation v Phase 1A: Cohort 10 Dose Escalation
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	superiority <sup>[32]</sup>
P-value	= 0.827259
Method	Wilcoxon (Mann-Whitney)
Parameter estimate	Hodges-Lehmann Estimator
Point estimate	-0.45
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.467
upper limit	0.95



Notes:

[32] - The Hodges-Lehmann estimator and 90% CI was calculated using the Moses approximation.

<b>Statistical analysis title</b>	Comparison of Cohorts 7 and 10 (120 mg) in C2D1
Statistical analysis description: Comparison of effect of food on Tmax between Cohort 7 (fed state) and Cohort 10 (fasted state) treatment arm groups of 120 mg ASTX029 in C1D1.	
Comparison groups	Phase 1A: Cohort 7 Dose Escalation v Phase 1A: Cohort 10 Dose Escalation
Number of subjects included in analysis	8
Analysis specification	Pre-specified
Analysis type	superiority <sup>[33]</sup>
P-value	= 0.51269
Method	Wilcoxon (Mann-Whitney)
Parameter estimate	Hodges-Lehmann Estimator
Point estimate	0.583
Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.45
upper limit	3.5

Notes:

[33] - The Hodges-Lehmann estimator and 90% CI was calculated using the Moses approximation.

### **Secondary: Phase 1: Inhibition of Phosphorylated Ribosomal S6 Kinase (pRSK) Protein in Response to ASTX029 Treatment in Tumor Biopsies as assessed by H Score**

End point title	Phase 1: Inhibition of Phosphorylated Ribosomal S6 Kinase (pRSK) Protein in Response to ASTX029 Treatment in Tumor Biopsies as assessed by H Score <sup>[34]</sup>
End point description: The protein expression level is quantified through the H-score, calculated from staining intensity within the target cell region. H-Score = (3x % of cells with staining graded 3) + (2x % of cells with staining graded 2) + % of cells with staining graded 1. H-Score ranges between 0 to 300. The H-score is for sum of cytoplasmic H-Score (C pRSK H-Score) and nuclear H-Scores (N pRSK H-Score). C pRSK H-Scores, and nuclear H-Scores were combined to give a single H-score. Pharmacodynamics analysis set included in the pharmacodynamic and biomarker analyses if they have received study drug and their samples were successfully collected and analysed. Subjects analysed is the number of subjects with data available for analysis. The data for this end point was collected and analysed for Phase 1B Dose Expansion cohort only.	
End point type	Secondary
End point timeframe: 4 hours post-dose on Day 8 of Cycle 2 (Cycle length = 21 days)	

Notes:

[34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

<b>End point values</b>	Phase 1B Dose Expansion			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: score on a scale				
arithmetic mean (standard deviation)	181.6 (± 172.31)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 1: Progression Free Survival (PFS)

End point title	Phase 1: Progression Free Survival (PFS) <sup>[35]</sup>
-----------------	----------------------------------------------------------

End point description:

The PFS was defined as the number of months from the start of the study treatment to disease progression or death, whichever occurs first. The PFS was analysed using a Kaplan-Meier method, with PFS time being censored on the date of the last disease assessment. The 90% CI for median PFS was provided using the Kaplan-Meier procedure. The efficacy analysis set included all subjects who received any amount of study drug. Here, "99999" indicates that the upper limit of 95% CI was not estimable because there was no event time for which the upper bound of the CI for the Kaplan-Meier estimate was less than 0.5.

End point type	Secondary
----------------	-----------

End point timeframe:

Every 2 cycles for the first 4 cycles and then every 4 cycles thereafter until disease progression (Up to 82 months)

Notes:

[35] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

<b>End point values</b>	Phase 1A: Cohort 1 Dose Escalation	Phase 1A: Cohort 2 Dose Escalation	Phase 1A: Cohort 3 Dose Escalation	Phase 1A: Cohort 4 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	5
Units: months				
median (confidence interval 95%)	1.3 (1.2 to 99999)	1.2 (1.2 to 99999)	8.1 (2.7 to 99999)	2.0 (1.1 to 99999)

<b>End point values</b>	Phase 1A: Cohort 5 Dose Escalation	Phase 1A: Cohort 6 Dose Escalation	Phase 1A: Cohort 7 Dose Escalation	Phase 1A: Cohort 8 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	6	3	3
Units: months				
median (confidence interval 95%)	1.2 (0.2 to 4.8)	1.3 (0.9 to 99999)	3.0 (1.2 to 99999)	1.1 (1.0 to 99999)

<b>End point values</b>	Phase 1A: Cohort 9 Dose Escalation	Phase 1A: Cohort 10 Dose Escalation	Phase 1A: Cohort 11 Dose Escalation	Phase 1A: Cohort 12 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	7	7
Units: months				
median (confidence interval 95%)	1.3 (1.0 to 99999)	2.3 (1.4 to 99999)	3.0 (0.7 to 5.3)	2.5 (0.4 to 4.0)

<b>End point values</b>	Phase 1B Dose Expansion			
Subject group type	Reporting group			
Number of subjects analysed	20			
Units: months				
median (confidence interval 95%)	1.4 (1.2 to 4.2)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 1: Overall Survival (OS)

End point title	Phase 1: Overall Survival (OS) <sup>[36]</sup>
-----------------	------------------------------------------------

End point description:

The OS was defined as the number of months from the day the subjects was randomised to the date of death (regardless of cause). Subjects without a documented death date were censored on the last date they were known to be alive. The OS was presented using a Kaplan-Meier estimate. The 90% CI for median OS was provided using the Kaplan-Meier procedure. The efficacy analysis set included all subjects who received any amount of study drug. Here, "99999" indicates that the median was not reached, and the lower limit and upper limit of 95% CI was not estimable because there was no event time for which the upper bound of the CI for the Kaplan-Meier estimate was less than 0.5.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 82 months

Notes:

[36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 1A: Cohort 1 Dose Escalation	Phase 1A: Cohort 2 Dose Escalation	Phase 1A: Cohort 3 Dose Escalation	Phase 1A: Cohort 4 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	5
Units: months				
median (confidence interval 95%)	13.5 (4.4 to 99999)	4.5 (3.4 to 99999)	10.2 (4.1 to 99999)	3.8 (2.1 to 99999)

End point values	Phase 1A: Cohort 5 Dose Escalation	Phase 1A: Cohort 6 Dose Escalation	Phase 1A: Cohort 7 Dose Escalation	Phase 1A: Cohort 8 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	6	3	3
Units: months				
median (confidence interval 95%)	2.1 (0.5 to 25.5)	11.3 (4.8 to 99999)	8.7 (2.6 to 99999)	2.0 (1.1 to 99999)

End point values	Phase 1A: Cohort 9 Dose Escalation	Phase 1A: Cohort 10 Dose Escalation	Phase 1A: Cohort 11 Dose Escalation	Phase 1A: Cohort 12 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	7	7
Units: months				
median (confidence interval 95%)	10.9 (1.3 to 99999)	99999 (-99999 to 99999)	14.8 (2.7 to 99999)	2.5 (1.2 to 13.1)

End point values	Phase 1B Dose Expansion			
Subject group type	Reporting group			
Number of subjects analysed	20			
Units: months				
median (confidence interval 95%)	15.1 (2.7 to 26.3)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 1: Disease Control Rate (DCR)

End point title	Phase 1: Disease Control Rate (DCR) <sup>[37]</sup>
-----------------	-----------------------------------------------------

End point description:

DCR was calculated as number of subjects whose best response was CR, PR, or stable disease (SD), divided by the total number of subjects evaluable for DCR analysis. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target/nontarget) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in sum of diameters of target lesions,

taking as reference the baseline sum diameters. Stable disease was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study. The efficacy analysis set included all subjects who received any amount of study drug. Analysis was based on subjects who were in efficacy analysis set and who had disease assessment at baseline and at least 1 follow-up disease assessment or subjects who died/stopped treatment. Percentages were rounded off to nearest single decimal place.

End point type	Secondary
----------------	-----------

End point timeframe:

Every 2 cycles for the first 4 cycles and then every 4 cycles thereafter until disease progression (Up to 82 months)

Notes:

[37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 1A: Cohort 1 Dose Escalation	Phase 1A: Cohort 2 Dose Escalation	Phase 1A: Cohort 3 Dose Escalation	Phase 1A: Cohort 4 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	5
Units: percentage of subjects				
number (confidence interval 90%)	0 (0 to 63.2)	0 (0 to 63.2)	100 (36.8 to 100)	40.0 (7.6 to 81.1)

End point values	Phase 1A: Cohort 5 Dose Escalation	Phase 1A: Cohort 6 Dose Escalation	Phase 1A: Cohort 7 Dose Escalation	Phase 1A: Cohort 8 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	6	3	3
Units: percentage of subjects				
number (confidence interval 90%)	20.0 (3.7 to 50.7)	16.7 (0.9 to 58.2)	66.7 (13.5 to 98.3)	33.3 (1.7 to 86.5)

End point values	Phase 1A: Cohort 9 Dose Escalation	Phase 1A: Cohort 10 Dose Escalation	Phase 1A: Cohort 11 Dose Escalation	Phase 1A: Cohort 12 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	7	7
Units: percentage of subjects				
number (confidence interval 90%)	33.3 (1.7 to 86.5)	33.3 (1.7 to 86.5)	85.7 (47.9 to 99.3)	42.9 (12.9 to 77.5)

End point values	Phase 1B Dose Expansion			
Subject group type	Reporting group			
Number of subjects analysed	20			
Units: percentage of subjects				
number (confidence interval 90%)	30.0 (14 to 50.8)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 1: Duration of Response (DoR)

End point title	Phase 1: Duration of Response (DoR) <sup>[38]</sup>
-----------------	-----------------------------------------------------

End point description:

Duration of response was calculated for all responders from the date of the earliest assessment of CR or PR to the date of relapse or death, whichever occurred earlier, or the last disease assessment date for subjects without a relapse or death. Duration of SD was calculated for subjects whose best response is CR, PR, or SD from the day study drug was first taken to the date of disease progression or death, whichever occurred earlier, or the last disease assessment for subjects without disease progression or death. The efficacy analysis set included all subjects who received any amount of study drug. Subjects analysed is the number of subjects with data available for analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Every 2 cycles for the first 4 cycles and then every 4 cycles thereafter until disease progression (Up to 82 months)

Notes:

[38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 1A: Cohort 1 Dose Escalation	Phase 1A: Cohort 2 Dose Escalation	Phase 1A: Cohort 3 Dose Escalation	Phase 1A: Cohort 4 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[39]</sup>	0 <sup>[40]</sup>	0 <sup>[41]</sup>	0 <sup>[42]</sup>
Units: days				
median (full range (min-max))	( to )	( to )	( to )	( to )

Notes:

[39] - Data was not estimable due to low number of subjects with events.

[40] - Data was not estimable due to low number of subjects with events.

[41] - Data was not estimable due to low number of subjects with events.

[42] - Data was not estimable due to low number of subjects with events.

End point values	Phase 1A: Cohort 5 Dose Escalation	Phase 1A: Cohort 6 Dose Escalation	Phase 1A: Cohort 7 Dose Escalation	Phase 1A: Cohort 8 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[43]</sup>	0 <sup>[44]</sup>	0 <sup>[45]</sup>	0 <sup>[46]</sup>
Units: days				
median (full range (min-max))	( to )	( to )	( to )	( to )

Notes:

[43] - Data was not estimable due to low number of subjects with events.

[44] - Data was not estimable due to low number of subjects with events.

[45] - Data was not estimable due to low number of subjects with events.

[46] - Data was not estimable due to low number of subjects with events.

End point values	Phase 1A: Cohort 9 Dose Escalation	Phase 1A: Cohort 10 Dose Escalation	Phase 1A: Cohort 11 Dose Escalation	Phase 1A: Cohort 12 Dose Escalation
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[47]</sup>	1	1	0 <sup>[48]</sup>
Units: days				
median (full range (min-max))	( to )	484.0 (484.0 to 484.0)	61.0 (61.0 to 61.0)	( to )

Notes:

[47] - Data was not estimable due to low number of subjects with events.

[48] - Data was not estimable due to low number of subjects with events.

End point values	Phase 1B Dose Expansion			
Subject group type	Reporting group			
Number of subjects analysed	2			
Units: days				
median (full range (min-max))	252.50 (252.0 to 253.0)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2: AUC0-24 of ASTX029

End point title	Phase 2: AUC0-24 of ASTX029 <sup>[49]</sup>
-----------------	---------------------------------------------

End point description:

The PK analysis set included all subjects who had received study drug with available plasma concentrations and PK parameters for ASTX029. Subjects analysed is the number of subjects with data available for analysis and 'n' represents unique number of subjects out of all the assessed subjects with data available at the specified timepoint. Here, "99999" indicates that geometric coefficient of variation was not estimable due to low number of subjects at specified time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose on Day 1 of Cycles 1, and 3; at 0.5,1,2,3,4,6 and 8 hours post-dose on Day 1 of Cycle 1, and at 0.5,1,2,4 and 8 post-dose on Day 1 of Cycle 3 (Cycle length = 21 days)

Notes:

[49] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 2: Cohort A	Phase 2: Cohort B	Phase 2: Cohort C	Phase 2: Cohort D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	24	13	9	9
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)				
C1D1 (n= 24,13,9,9,28,12)	12200 (± 69.1)	13000 (± 57.2)	9570 (± 80.3)	8730 (± 100.0)

Cycle 3 Day 1 (C3D1) (n= 15,4,1,4,16,5)	11600 (± 76.1)	27600 (± 47.3)	11500 (± 99999)	12800 (± 36.2)
-----------------------------------------	----------------	----------------	-----------------	----------------

End point values	Phase 2: Cohort E	Phase 2: Cohort F		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	12		
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)				
C1D1 (n= 24,13,9,9,28,12)	12000 (± 83.3)	13400 (± 71.3)		
Cycle 3 Day 1 (C3D1) (n= 15,4,1,4,16,5)	12300 (± 88.7)	15300 (± 52.4)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2: AUC0-last of ASTX029

End point title	Phase 2: AUC0-last of ASTX029 <sup>[50]</sup>
-----------------	-----------------------------------------------

End point description:

The PK analysis set included all subjects who had received study drug with available plasma concentrations and PK parameters for ASTX029. Here, subjects analysed is the number of subjects with data available for analysis and 'n' represents unique number of subjects out of all the assessed subjects with data available at the specified timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose on Day 1 of Cycles 1, and 3; at 0.5,1,2,3,4,6 and 8 hours post-dose on Day 1 of Cycle 1, and at 0.5,1,2,4 and 8 post-dose on Day 1 of Cycle 3 (Cycle length = 21 days)

Notes:

[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 2: Cohort A	Phase 2: Cohort B	Phase 2: Cohort C	Phase 2: Cohort D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	32	15	12	9
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)				
C1D1 (n= 32,15,12,9,32,14)	12300 (± 70.4)	15000 (± 68.5)	7800 (± 81.7)	8730 (± 100.0)
C3D1 (n= 19,7,5,5,20,5)	8090 (± 214.2)	13600 (± 114.5)	1960 (± 369.9)	11700 (± 31.5)

End point values	Phase 2: Cohort E	Phase 2: Cohort F		
------------------	----------------------	----------------------	--	--



Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	14		
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)				
C1D1 (n= 32,15,12,9,32,14) C3D1 (n= 19,7,5,5,20,5)	11500 (± 80.3) 10400 (± 86.4)	12700 (± 66.9) 14000 (± 52.1)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 2: AUC0-inf of ASTX029

End point title	Phase 2: AUC0-inf of ASTX029 <sup>[51]</sup>
-----------------	----------------------------------------------

End point description:

The PK analysis set included all subjects who had received study drug with available plasma concentrations and PK parameters for ASTX029. Here, subjects analysed is the number of subjects with data available for analysis. Data for AUC0-inf was collected and analysed for C1D1 only.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose on Day 1 of Cycle 1: and at 0.5,1,2,3,4,6 and 8 hours post-dose on Day 1 of Cycle 1 (Cycle length = 21 days)

Notes:

[51] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 2: Cohort A	Phase 2: Cohort B	Phase 2: Cohort C	Phase 2: Cohort D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	13	6	7
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)	12500 (± 66.6)	17100 (± 60.4)	10700 (± 103.0)	11800 (± 62.5)

End point values	Phase 2: Cohort E	Phase 2: Cohort F		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	13		
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)	12500 (± 74.5)	13300 (± 67.5)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2: Cmax of ASTX029

End point title	Phase 2: Cmax of ASTX029 <sup>[52]</sup>
-----------------	------------------------------------------

End point description:

The PK analysis set included all subjects who had received study drug with available plasma concentrations and PK parameters for ASTX029. Here, subjects analysed is the number of subjects with data available for analysis and 'n' represents unique number of subjects out of all the assessed subjects with data available at the specified timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose on Day 1 of Cycles 1, and 3; at 0.5,1,2,3,4,6 and 8 hours post-dose on Day 1 of Cycle 1, and at 0.5,1,2,4 and 8 post-dose on Day 1 of Cycle 3 (Cycle length = 21 days)

Notes:

[52] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 2: Cohort A	Phase 2: Cohort B	Phase 2: Cohort C	Phase 2: Cohort D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	32	15	12	9
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
C1D1 (n= 32,15,12,9,32,14)	4430 (± 70.9)	5930 (± 81.3)	2890 (± 97.7)	2840 (± 239.4)
C3D1 (n= 19,7,5,5,20,5)	3280 (± 179.3)	4730 (± 150.7)	780 (± 464.1)	5090 (± 43.5)

End point values	Phase 2: Cohort E	Phase 2: Cohort F		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	14		
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
C1D1 (n= 32,15,12,9,32,14)	4660 (± 113.6)	5620 (± 65.7)		
C3D1 (n= 19,7,5,5,20,5)	4410 (± 110.4)	4860 (± 66.8)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2: Cmin of ASTX029

End point title	Phase 2: Cmin of ASTX029 <sup>[53]</sup>
-----------------	------------------------------------------

End point description:

The PK analysis set included all subjects who had received study drug with available plasma concentrations and PK parameters for ASTX029. Here, subjects analysed is the number of subjects with data available for analysis. Data for Cmin was calculated and analysed for C3D1 only.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose on Day 1 of Cycle 3; and at 0.5,1,2,4 and 8 post-dose on Day 1 of Cycle 3 (Cycle length = 21 days)

Notes:

[53] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 2: Cohort A	Phase 2: Cohort B	Phase 2: Cohort C	Phase 2: Cohort D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	19	7	5	5
Units: ng/mL				
geometric mean (geometric coefficient of variation)	189 (± 181.0)	260 (± 95.5)	81.7 (± 102.0)	144 (± 78.2)

End point values	Phase 2: Cohort E	Phase 2: Cohort F		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	20	5		
Units: ng/mL				
geometric mean (geometric coefficient of variation)	205 (± 104.9)	246 (± 67.6)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2: Tmax of ASTX029

End point title	Phase 2: Tmax of ASTX029 <sup>[54]</sup>
-----------------	------------------------------------------

End point description:

The PK analysis set included all subjects who had received study drug with available plasma concentrations and PK parameters for ASTX029. Here, subjects analysed is the number of subjects with data available for analysis and 'n' represents unique number of subjects out of all the assessed subjects with data available at the specified timepoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose on Day 1 of Cycles 1, and 3; at 0.5,1,2,3,4,6 and 8 hours post-dose on Day 1 of Cycle 1, and at 0.5,1,2,4 and 8 post-dose on Day 1 of Cycle 3 (Cycle length = 21 days)

Notes:

[54] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 2: Cohort A	Phase 2: Cohort B	Phase 2: Cohort C	Phase 2: Cohort D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	32	15	12	9
Units: hours				
median (full range (min-max))				
C1D1 (n= 32,15,12,9,32,14)	2.03 (0.50 to 4.08)	1.95 (0.95 to 6.08)	2.90 (0.50 to 7.55)	2.07 (0.92 to 7.90)
C3D1 (n= 19,7,5,5,20,5)	2.00 (0.97 to 4.05)	2.03 (0.58 to 4.05)	2.03 (0.67 to 7.53)	1.90 (1.00 to 2.00)

End point values	Phase 2: Cohort E	Phase 2: Cohort F		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	14		
Units: hours				
median (full range (min-max))				
C1D1 (n= 32,15,12,9,32,14)	2.00 (0.40 to 4.07)	2.00 (1.00 to 3.87)		
C3D1 (n= 19,7,5,5,20,5)	2.00 (0.48 to 4.17)	1.97 (0.95 to 4.00)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2: T1/2 of ASTX029

End point title	Phase 2: T1/2 of ASTX029 <sup>[55]</sup>
-----------------	------------------------------------------

End point description:

The PK analysis set included all subjects who had received study drug with available plasma concentrations and PK parameters for ASTX029. Here, subjects analysed is the number of subjects with data available for analysis. Data for T1/2 was collected and analysed for C1D1 only.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose on Day 1 of Cycle 1; at 0.5,1,2,3,4,6 and 8 hours post-dose on Day 1 of Cycle 1 (Cycle length = 21 days)

Notes:

[55] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 2: Cohort A	Phase 2: Cohort B	Phase 2: Cohort C	Phase 2: Cohort D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	13	6	7
Units: hours				
geometric mean (geometric coefficient of variation)	2.68 (± 68.8)	3.45 (± 52.0)	3.79 (± 19.1)	3.73 (± 12.2)

End point values	Phase 2: Cohort E	Phase 2: Cohort F		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	13		
Units: hours				
geometric mean (geometric coefficient of variation)	3.64 ( $\pm$ 43.2)	3.39 ( $\pm$ 48.2)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2: Progression Free Survival

End point title	Phase 2: Progression Free Survival <sup>[56]</sup>
-----------------	----------------------------------------------------

End point description:

The PFS was defined as the number of months from the start of the study treatment to disease progression or death, whichever occurs first. The PFS was analysed using a Kaplan-Meier method, with PFS time being censored on the date of the last disease assessment. The 90% CI for median PFS was provided using the Kaplan-Meier procedure. The efficacy analysis set included all subjects who received any amount of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Every 2 cycles for the first 4 cycles and then every 4 cycles thereafter until disease progression (Up to 82 months)

Notes:

[56] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 2: Cohort A	Phase 2: Cohort B	Phase 2: Cohort C	Phase 2: Cohort D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	32	15	12	9
Units: months				
median (confidence interval 95%)	2.8 (1.5 to 5.5)	2.8 (0.9 to 4.6)	1.7 (0.8 to 6.1)	8.0 (1.0 to 9.6)

End point values	Phase 2: Cohort E	Phase 2: Cohort F		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	14		
Units: months				
median (confidence interval 95%)	3.5 (2.2 to 6.2)	2.0 (1.2 to 5.5)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 2: Overall Survival

End point title	Phase 2: Overall Survival <sup>[57]</sup>
-----------------	-------------------------------------------

End point description:

The OS was defined as the number of months from the months the subjects was randomised to the date of death (regardless of cause). Subjects without a documented death date were censored on the last date they were known to be alive. The OS was presented using a Kaplan-Meier estimate. The 90% CI for median OS was provided using the Kaplan-Meier procedure. The efficacy analysis set included all subjects who received any amount of study drug. Here, "99999" indicates that the upper limit of 95% CI was not estimable because there was no event time for which the upper bound of the CI for the Kaplan-Meier estimate was less than 0.5.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 82 months

Notes:

[57] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 2: Cohort A	Phase 2: Cohort B	Phase 2: Cohort C	Phase 2: Cohort D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	32	15	12	9
Units: months				
median (confidence interval 95%)	8.0 (4.4 to 13.6)	4.9 (1.5 to 10.1)	6.1 (1.1 to 19.3)	11.6 (2.0 to 99999)

End point values	Phase 2: Cohort E	Phase 2: Cohort F		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	14		
Units: months				
median (confidence interval 95%)	11.2 (6.8 to 99999)	9.9 (3.5 to 15.9)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 2: Disease Control Rate

End point title	Phase 2: Disease Control Rate <sup>[58]</sup>
-----------------	-----------------------------------------------

End point description:

DCR was calculated as number of subjects whose best response was CR, PR, or SD, divided by the total number of subjects evaluable for DCR analysis. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable disease was defined as neither sufficient shrinkage to

qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. The efficacy analysis set included all subjects who received any amount of study drug. The DCR analysis was based on subjects who were in the efficacy analysis set and who had disease assessment at baseline and at least 1 follow-up disease assessment or subjects who died or stopped treatment before the first scheduled disease assessment due to clinical progression or toxicity.

End point type	Secondary
----------------	-----------

End point timeframe:

Every 2 cycles for the first 4 cycles and then every 4 cycles thereafter until disease progression (Up to 82 months)

Notes:

[58] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 2: Cohort A	Phase 2: Cohort B	Phase 2: Cohort C	Phase 2: Cohort D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	32	15	12	9
Units: percentage of subjects				
number (confidence interval 95%)	65.6 (49.6 to 79.4)	60.0 (36 to 80.9)	41.7 (18.1 to 68.5)	77.8 (45 to 95.9)

End point values	Phase 2: Cohort E	Phase 2: Cohort F		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	14		
Units: percentage of subjects				
number (confidence interval 95%)	68.8 (52.8 to 82)	42.9 (20.6 to 67.5)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2: Duration of Response

End point title	Phase 2: Duration of Response <sup>[59]</sup>
-----------------	-----------------------------------------------

End point description:

Duration of response was calculated for all responders from the date of the earliest assessment of CR or PR to the date of relapse or death, whichever occurred earlier, or the last disease assessment date for subjects without a relapse or death. Duration of SD was calculated for subjects whose best response is CR, PR, or SD from the day study drug was first taken to the date of disease progression or death, whichever occurred earlier, or the last disease assessment for subjects without disease progression or death. The efficacy analysis set included all subjects who received any amount of study drug. Subjects analysed is the number of subjects with data available for analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Every 2 cycles for the first 4 cycles and then every 4 cycles thereafter until disease progression (Up to 82 months)

Notes:

[59] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The data is reported only for the treatment arm groups applicable for this end point.

End point values	Phase 2: Cohort A	Phase 2: Cohort B	Phase 2: Cohort C	Phase 2: Cohort D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	0 <sup>[60]</sup>	1	0 <sup>[61]</sup>
Units: days				
median (full range (min-max))	193.00 (65.0 to 219.0)	( to )	144.00 (144.00 to 144.00)	( to )

Notes:

[60] - Data was not estimable due to low number of subjects with events.

[61] - Data was not estimable due to low number of subjects with events.

End point values	Phase 2: Cohort E	Phase 2: Cohort F		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4	1		
Units: days				
median (full range (min-max))	189.50 (102.0 to 260.0)	750.00 (750.00 to 750.00)		

## Statistical analyses

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug up to end of the study (Up to 82 months)

Adverse event reporting additional description:

The safety analysis set included data from all subjects who received any amount of study drug.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	27.0
--------------------	------

### Reporting groups

Reporting group title	Phase 1A: Cohort 1 Dose Escalation
-----------------------	------------------------------------

Reporting group description:

Subjects received ASTX029 10 milligrams (mg), powder in bottle (PiB), orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.

Reporting group title	Phase 1A: Cohort 2 Dose Escalation
-----------------------	------------------------------------

Reporting group description:

Subjects received ASTX029 20 mg, PiB, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.

Reporting group title	Phase 1A: Cohort 3 Dose Escalation
-----------------------	------------------------------------

Reporting group description:

Subjects received ASTX029 60 mg, PiB, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.

Reporting group title	Phase 1A: Cohort 4 Dose Escalation
-----------------------	------------------------------------

Reporting group description:

Subjects received ASTX029 120 mg, PiB, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.

Reporting group title	Phase 1A: Cohort 5 Dose Escalation
-----------------------	------------------------------------

Reporting group description:

Subjects received ASTX029 200 mg, orally, PiB, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.

Reporting group title	Phase 1A: Cohort 6 Dose Escalation
-----------------------	------------------------------------

Reporting group description:

Subjects received ASTX029 80 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.

Reporting group title	Phase 1A: Cohort 7 Dose Escalation
-----------------------	------------------------------------

Reporting group description:

Subjects received ASTX029 120 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fed state.

Reporting group title	Phase 1A: Cohort 8 Dose Escalation
-----------------------	------------------------------------

Reporting group description:

Subjects received ASTX029 40 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.

Reporting group title	Phase 1A: Cohort 9 Dose Escalation
-----------------------	------------------------------------

Reporting group description:

Subjects received ASTX029 80 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.

Reporting group title	Phase 1A: Cohort 10 Dose Escalation
-----------------------	-------------------------------------

Reporting group description:

Subjects received ASTX029 120 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.

Reporting group title	Phase 1A: Cohort 11 Dose Escalation
-----------------------	-------------------------------------

Reporting group description:

Subjects received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.

Reporting group title	Phase 1A: Cohort 12 Dose Escalation
-----------------------	-------------------------------------

Reporting group description:

Subjects received ASTX029 280 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.

Reporting group title	Phase 1B Dose Expansion
-----------------------	-------------------------

Reporting group description:

Subjects received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months, under fasted state.

Reporting group title	Phase 2: Cohort A
-----------------------	-------------------

Reporting group description:

Subjects with neuroblastoma RAS (NRAS)-mutant melanoma received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.

Reporting group title	Phase 2: Cohort B
-----------------------	-------------------

Reporting group description:

Subjects with Kirsten RAS (KRAS)-mutant or KRAS-amplified non-small cell lung cancer (NSCLC) received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.

Reporting group title	Phase 2: Cohort C
-----------------------	-------------------

Reporting group description:

Subjects with B isoform of RAF kinase (BRAF) V600-mutant cancers (non-colorectal cancers) received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.

Reporting group title	Phase 2: Cohort D
-----------------------	-------------------

Reporting group description:

Subjects with BRAF-fusion cancers received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.

Reporting group title	Phase 2: Cohort E
-----------------------	-------------------

Reporting group description:

Subjects with gynecological cancers with alterations in the mitogen-activated protein kinase (MAPK) pathway received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.

Reporting group title	Phase 2: Cohort F
-----------------------	-------------------

Reporting group description:

Subjects with tumors that were characterized by other gene aberrations (that upregulate the MAPK signal pathway) received ASTX029 200 mg, tablets, orally, once daily, on Days 1-21 of each 21-day cycle, up to median duration of 1.6 months.

Serious adverse events	Phase 1A: Cohort 1 Dose Escalation	Phase 1A: Cohort 2 Dose Escalation	Phase 1A: Cohort 3 Dose Escalation
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	2 / 3 (66.67%)
number of deaths (all causes)	3	2	3
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Embolism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism venous			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic dissection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organ failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Respiratory disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wheezing			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Mental status changes			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			

Alanine aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal stoma output decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Nervous system disorders</b>			
Intracranial mass			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Blood and lymphatic system disorders</b>			
Anaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal disorders</b>			
Abdominal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Intestinal obstruction				
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Large intestinal obstruction				
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Erosive duodenitis				
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage				
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Ascites				
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Colitis				
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Nausea				
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Constipation				
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Gastrointestinal haemorrhage				



subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal strangulated hernia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal impairment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis infectious			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Wound infection				
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Sepsis				
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Urinary tract infection bacterial				
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Biliary tract infection				
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Cellulitis				
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Device related infection				
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Pneumonia aspiration				
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Urosepsis				
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Pyelonephritis				

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypoglycaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Phase 1A: Cohort 4 Dose Escalation	Phase 1A: Cohort 5 Dose Escalation	Phase 1A: Cohort 6 Dose Escalation
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 5 (40.00%)	7 / 10 (70.00%)	1 / 6 (16.67%)
number of deaths (all causes)	3	9	4
number of deaths resulting from adverse events		2	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Embolic			

subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism venous			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic dissection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			

subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organ failure			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			
subjects affected / exposed	1 / 5 (20.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory disorder			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			

subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wheezing			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Mental status changes			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase			

increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal stoma output decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Intracranial mass			



subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Large intestinal obstruction			

subjects affected / exposed	1 / 5 (20.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erosive duodenitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			

subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal strangulated hernia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			

subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal impairment			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 5 (0.00%)	4 / 10 (40.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis infectious			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 5 (20.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	1 / 5 (20.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Sepsis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection bacterial			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary tract infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			

Hypoglycaemia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Phase 1A: Cohort 7 Dose Escalation	Phase 1A: Cohort 8 Dose Escalation	Phase 1A: Cohort 9 Dose Escalation
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 3 (66.67%)	0 / 3 (0.00%)	1 / 3 (33.33%)
number of deaths (all causes)	3	3	3
number of deaths resulting from adverse events			1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Embolism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism venous			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic dissection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organ failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			



subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wheezing			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Mental status changes			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastrointestinal stoma output decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Intracranial mass			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erosive duodenitis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Colitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal strangulated hernia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal impairment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis infectious			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Urinary tract infection bacterial subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary tract infection subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders Hypoglycaemia subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			

subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Phase 1A: Cohort 10 Dose Escalation	Phase 1A: Cohort 11 Dose Escalation	Phase 1A: Cohort 12 Dose Escalation
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 3 (33.33%)	3 / 7 (42.86%)	1 / 7 (14.29%)
number of deaths (all causes)	1	5	7
number of deaths resulting from adverse events		1	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Embolism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism venous			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic dissection			



subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organ failure			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory disorder			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wheezing			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Mental status changes			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal stoma output decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Intracranial mass			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erosive duodenitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Ascites			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal strangulated hernia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 3 (33.33%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal impairment			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis infectious			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection bacterial			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0



Biliary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypoglycaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Phase 1B Dose Expansion	Phase 2: Cohort A	Phase 2: Cohort B
Total subjects affected by serious adverse events			
subjects affected / exposed	9 / 20 (45.00%)	11 / 32 (34.38%)	5 / 15 (33.33%)
number of deaths (all causes)	13	23	13
number of deaths resulting from adverse events		1	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Embolism			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism venous			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic dissection			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			

subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organ failure			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Respiratory, thoracic and mediastinal disorders			

Acute respiratory failure			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory disorder			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			

subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wheezing			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Mental status changes			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal stoma output decreased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			

subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Intracranial mass			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			

subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Blood and lymphatic system disorders</b>			
<b>Anaemia</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Leukocytosis</b>			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal disorders</b>			
<b>Abdominal pain</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Intestinal obstruction</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Large intestinal obstruction</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Erosive duodenitis</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Upper gastrointestinal haemorrhage</b>			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Ascites</b>			

subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	1 / 20 (5.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 20 (5.00%)	1 / 32 (3.13%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 20 (0.00%)	2 / 32 (6.25%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal strangulated hernia			



subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal impairment			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			

Back pain			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis infectious			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 20 (0.00%)	2 / 32 (6.25%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection bacterial			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary tract infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			

subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypoglycaemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			

subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Phase 2: Cohort C	Phase 2: Cohort D	Phase 2: Cohort E
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 12 (33.33%)	3 / 9 (33.33%)	12 / 32 (37.50%)
number of deaths (all causes)	10	5	14
number of deaths resulting from adverse events			1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Embolism			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism venous			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic dissection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			

subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organ failure			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pneumonitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory disorder			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			

subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wheezing			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Mental status changes			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal stoma output decreased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture			

subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Intracranial mass			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			



Anaemia			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erosive duodenitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			

subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal strangulated hernia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			

subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pancreatitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal impairment			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infections and infestations Pneumonia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 12 (0.00%) 0 / 0 0 / 0	0 / 9 (0.00%) 0 / 0 0 / 0	0 / 32 (0.00%) 0 / 0 0 / 0
Enterocolitis infectious subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 12 (0.00%) 0 / 0 0 / 0	0 / 9 (0.00%) 0 / 0 0 / 0	0 / 32 (0.00%) 0 / 0 0 / 0
Urinary tract infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 12 (0.00%) 0 / 0 0 / 0	0 / 9 (0.00%) 0 / 0 0 / 0	1 / 32 (3.13%) 0 / 3 0 / 0
Wound infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 12 (0.00%) 0 / 0 0 / 0	0 / 9 (0.00%) 0 / 0 0 / 0	0 / 32 (0.00%) 0 / 0 0 / 0
Sepsis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 12 (0.00%) 0 / 0 0 / 0	0 / 9 (0.00%) 0 / 0 0 / 0	0 / 32 (0.00%) 0 / 0 0 / 0
Urinary tract infection bacterial subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 12 (0.00%) 0 / 0 0 / 0	0 / 9 (0.00%) 0 / 0 0 / 0	0 / 32 (0.00%) 0 / 0 0 / 0
Biliary tract infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 12 (0.00%) 0 / 0 0 / 0	0 / 9 (0.00%) 0 / 0 0 / 0	0 / 32 (0.00%) 0 / 0 0 / 0
Cellulitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 12 (0.00%) 0 / 0 0 / 0	1 / 9 (11.11%) 0 / 1 0 / 0	1 / 32 (3.13%) 0 / 1 0 / 0
Device related infection			

subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypoglycaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Phase 2: Cohort F		
-------------------------------	-------------------	--	--

Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 14 (28.57%)		
number of deaths (all causes)	11		
number of deaths resulting from adverse events	2		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Embolism			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Embolism venous			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aortic dissection			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypertension			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypotension			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Non-cardiac chest pain			

subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malaise			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chest pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fatigue			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Organ failure			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aspiration			

subjects affected / exposed	0 / 14 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory failure				
subjects affected / exposed	0 / 14 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory disorder				
subjects affected / exposed	0 / 14 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dyspnoea				
subjects affected / exposed	1 / 14 (7.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pleural effusion				
subjects affected / exposed	0 / 14 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pulmonary embolism				
subjects affected / exposed	0 / 14 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypoxia				
subjects affected / exposed	0 / 14 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Haemoptysis				
subjects affected / exposed	0 / 14 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Wheezing				



subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Mental status changes			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal stoma output decreased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Fracture			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hip fracture			

subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atrial flutter			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Intracranial mass			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Encephalopathy			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ischaemic stroke			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebrovascular accident			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Leukocytosis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal obstruction			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Large intestinal obstruction			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Erosive duodenitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ascites			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nausea			

subjects affected / exposed	0 / 14 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Constipation				
subjects affected / exposed	0 / 14 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal haemorrhage				
subjects affected / exposed	0 / 14 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vomiting				
subjects affected / exposed	0 / 14 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diarrhoea				
subjects affected / exposed	1 / 14 (7.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Abdominal pain upper				
subjects affected / exposed	0 / 14 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Abdominal strangulated hernia				
subjects affected / exposed	0 / 14 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastritis				
subjects affected / exposed	1 / 14 (7.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Inguinal hernia				

subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal perforation			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 1		
Hydronephrosis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal impairment			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Enterocolitis infectious				
subjects affected / exposed	0 / 14 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Urinary tract infection				
subjects affected / exposed	0 / 14 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Wound infection				
subjects affected / exposed	0 / 14 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sepsis				
subjects affected / exposed	0 / 14 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Urinary tract infection bacterial				
subjects affected / exposed	0 / 14 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Biliary tract infection				
subjects affected / exposed	0 / 14 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cellulitis				
subjects affected / exposed	0 / 14 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Device related infection				
subjects affected / exposed	0 / 14 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia aspiration				

subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urosepsis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Hypoglycaemia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyponatraemia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperglycaemia			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hyperkalaemia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Phase 1A: Cohort 1 Dose Escalation	Phase 1A: Cohort 2 Dose Escalation	Phase 1A: Cohort 3 Dose Escalation
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 3 (100.00%)	3 / 3 (100.00%)	3 / 3 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	2
Cancer pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Phlebitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Deep vein thrombosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Peripheral coldness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lymphoedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Embolism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			



Asthenia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Chills			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	2 / 3 (66.67%)
occurrences (all)	0	1	2
Non-cardiac chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Catheter site erythema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Generalised oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nodule			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Secretion discharge subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Catheter site pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Chest discomfort subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Injection site bruising subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Localised oedema subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Face oedema subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Thirst subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Gait disturbance subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Peripheral swelling subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Drug hypersensitivity			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Reproductive system and breast disorders			
Balanoposthitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Breast pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Pleural effusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Dysphonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Oropharyngeal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Dyspnoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Epistaxis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pneumothorax			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypercapnia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lung opacity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nasal dryness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pneumonitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tachypnoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hiccups			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dyspnoea exertional			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Haemoptysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Laryngeal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Respiratory distress			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Delirium			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Confusional state			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Agitation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Mental status changes			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Mental disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sleep disorder			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	1	0	1
Alanine aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 3 (33.33%)	2 / 3 (66.67%)	0 / 3 (0.00%)
occurrences (all)	2	2	0
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood bilirubin increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood cholesterol increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lipase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Weight decreased			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Blood glucose increased			

subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
White blood cell count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
International normalised ratio increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ammonia increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood magnesium decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ejection fraction decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Weight increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Amylase increased			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood corticotrophin decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood creatine increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood iron decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood potassium increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hepatic enzyme increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Post procedural complication			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Post procedural discharge			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Stoma site haemorrhage			



subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Post procedural contusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Venous injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Spinal compression fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Limb injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin abrasion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Congenital, familial and genetic disorders			
Phimosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Sinus tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Angina pectoris			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Supraventricular tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sinus bradycardia			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Nervous system disorders			
Dysgeusia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Memory impairment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neuralgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Migraine			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Ophthalmic migraine			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Burning sensation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Post herpetic neuralgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Seizure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Aphasia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Embolic stroke			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Balance disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dizziness postural			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 3 (66.67%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	2	3	0
Leukocytosis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Anaemia of malignant disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Thrombocytosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Iron deficiency anaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Thrombotic thrombocytopenic purpura			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Middle ear effusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tinnitus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Inner ear disorder			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Eye disorders			
Dyschromatopsia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Periorbital oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Photophobia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Vision blurred			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Visual field defect			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinal degeneration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Cataract			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Diplopia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Macular detachment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinopathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Visual impairment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Central serous chorioretinopathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Detachment of retinal pigment epithelium			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Exophthalmos			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Subretinal fluid			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Visual acuity reduced			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eye disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinal detachment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Presbyopia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vitreous floaters			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blepharitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Keratitis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lacrimation increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ocular discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Visual brightness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	3 / 3 (100.00%)
occurrences (all)	0	1	4
Diarrhoea			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)
occurrences (all)	0	1	2
Constipation			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Abdominal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lip oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Abdominal discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ascites			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0

Dry mouth			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	1	0	1
Dysphagia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Ileus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastric ulcer			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cheilitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oral dysaesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Swollen tongue			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0



Rectal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Glossodynia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Large intestinal ulcer			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Large intestinal polyp			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Melaena			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tongue oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retching			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Angular cheilitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Colitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Gastritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lip blister			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Odynophagia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oesophagitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Small intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tongue haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Hepatic pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypertransaminaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Rash maculo-papular			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Onychoclasia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin fissures			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin indentation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Scab			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin hyperpigmentation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Onycholysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rosacea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin ulcer			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nail disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash macular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Haematuria			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Chromaturia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Acute kidney injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hydronephrosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Proteinuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Pain in extremity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Arthralgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Back pain			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Flank pain			

subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Joint swelling			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Bone pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Limb mass			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Spinal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Bursitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Connective tissue disorder			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Joint range of motion decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Osteonecrosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Osteoporosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Paronychia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Wound infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ear infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Rash pustular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Bacteraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Injection site infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
COVID-19			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Coronavirus infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0



Nasopharyngitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Metapneumovirus infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Periorbital infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urethritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperkalaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypocalcaemia			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyponatraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dehydration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypophosphataemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypercalcaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperuricaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypomagnesaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypoproteinaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cachexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Malnutrition			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Phase 1A: Cohort 4 Dose Escalation	Phase 1A: Cohort 5 Dose Escalation	Phase 1A: Cohort 6 Dose Escalation
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 5 (100.00%)	8 / 10 (80.00%)	6 / 6 (100.00%)

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Cancer pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Vascular disorders			
Hypotension			
subjects affected / exposed	1 / 5 (20.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Phlebitis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Deep vein thrombosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Peripheral coldness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lymphoedema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Embolism			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0

Chills			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Fatigue			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Oedema			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Pyrexia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Catheter site erythema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Generalised oedema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nodule			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Secretion discharge			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Catheter site pain subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Chest discomfort subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Injection site bruising subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Localised oedema subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Pain subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Face oedema subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Thirst subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Gait disturbance subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Peripheral swelling subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Drug hypersensitivity subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Reproductive system and breast disorders			

Balanoposthitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Breast pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Pleural effusion			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Productive cough			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Cough			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dysphonia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	1 / 5 (20.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Wheezing			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Dyspnoea			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			

subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pneumothorax			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypercapnia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lung opacity			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nasal dryness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pneumonitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tachypnoea			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hiccups			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dyspnoea exertional			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Haemoptysis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Laryngeal haemorrhage subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Respiratory distress subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Psychiatric disorders			
Insomnia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	2 / 10 (20.00%) 2	0 / 6 (0.00%) 0
Delirium subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 10 (10.00%) 1	0 / 6 (0.00%) 0
Confusional state subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Agitation subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Mental status changes subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Anxiety subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Depression subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Mental disorder subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Sleep disorder subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Investigations			



Aspartate aminotransferase increased			
subjects affected / exposed	1 / 5 (20.00%)	5 / 10 (50.00%)	2 / 6 (33.33%)
occurrences (all)	1	6	3
Alanine aminotransferase increased			
subjects affected / exposed	1 / 5 (20.00%)	3 / 10 (30.00%)	1 / 6 (16.67%)
occurrences (all)	2	3	1
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 5 (20.00%)	2 / 10 (20.00%)	1 / 6 (16.67%)
occurrences (all)	2	2	1
Activated partial thromboplastin time prolonged			
subjects affected / exposed	1 / 5 (20.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Blood bilirubin increased			
subjects affected / exposed	1 / 5 (20.00%)	1 / 10 (10.00%)	1 / 6 (16.67%)
occurrences (all)	1	1	1
Blood cholesterol increased			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Lipase increased			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Platelet count decreased			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Weight decreased			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Blood glucose increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			

subjects affected / exposed	1 / 5 (20.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
International normalised ratio increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Ammonia increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood magnesium decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ejection fraction decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Weight increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Amylase increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood corticotrophin decreased			

subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood creatine increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood iron decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood potassium increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hepatic enzyme increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Post procedural complication			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Post procedural discharge			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Stoma site haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Post procedural contusion			

subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Venous injury subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Spinal compression fracture subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Limb injury subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Skin abrasion subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Congenital, familial and genetic disorders Phimosis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Cardiac disorders Sinus tachycardia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 10 (10.00%) 1	0 / 6 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Angina pectoris subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Supraventricular tachycardia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Sinus bradycardia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Nervous system disorders			

Dysgeusia			
subjects affected / exposed	0 / 5 (0.00%)	2 / 10 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Memory impairment			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Neuralgia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Dizziness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Migraine			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ophthalmic migraine			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Burning sensation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Post herpetic neuralgia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Seizure			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Somnolence			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Aphasia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Embolic stroke			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Balance disorder			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dizziness postural			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 5 (40.00%)	3 / 10 (30.00%)	0 / 6 (0.00%)
occurrences (all)	2	4	0
Leukocytosis			
subjects affected / exposed	1 / 5 (20.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Neutropenia			

subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Anaemia of malignant disease			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Thrombocytosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Iron deficiency anaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Thrombotic thrombocytopenic purpura			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Middle ear effusion			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tinnitus			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Inner ear disorder			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eye disorders			

Dyschromatopsia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Periorbital oedema			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Photophobia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Vision blurred			
subjects affected / exposed	1 / 5 (20.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Visual field defect			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Retinal degeneration			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Cataract			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Diplopia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Macular detachment			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Retinopathy			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Visual impairment			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Central serous chorioretinopathy			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0



Detachment of retinal pigment epithelium			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Exophthalmos			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Subretinal fluid			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Visual acuity reduced			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eye disorder			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Retinal detachment			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Presbyopia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vitreous floaters			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blepharitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Keratitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lacrimation increased			

subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ocular discomfort			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Visual brightness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	3 / 5 (60.00%)	4 / 10 (40.00%)	1 / 6 (16.67%)
occurrences (all)	3	5	1
Diarrhoea			
subjects affected / exposed	1 / 5 (20.00%)	3 / 10 (30.00%)	2 / 6 (33.33%)
occurrences (all)	2	4	2
Constipation			
subjects affected / exposed	0 / 5 (0.00%)	2 / 10 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Abdominal pain			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Lip oedema			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Vomiting			
subjects affected / exposed	2 / 5 (40.00%)	1 / 10 (10.00%)	1 / 6 (16.67%)
occurrences (all)	3	1	1
Abdominal discomfort			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ascites			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Dysphagia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastroesophageal reflux disease			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ileus			
subjects affected / exposed	1 / 5 (20.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Gastric ulcer			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Cheilitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oral dysaesthesia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Swollen tongue			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Gastrointestinal haemorrhage subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Glossodynia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Large intestinal ulcer subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Large intestinal polyp subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Melaena subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Stomatitis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Tongue oedema subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Haemorrhoids subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Retching subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Angular cheilitis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Colitis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Gastritis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0

Lip blister subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Odynophagia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Oesophagitis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Small intestinal obstruction subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Tongue haemorrhage subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Toothache subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Hepatobiliary disorders Hepatic pain subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Hyperbilirubinaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Hypertransaminasaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Skin and subcutaneous tissue disorders Pruritus subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	2 / 10 (20.00%) 2	0 / 6 (0.00%) 0
Rash maculo-papular subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	2 / 10 (20.00%) 4	1 / 6 (16.67%) 1
Alopecia			

subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Erythema			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Onychoclasia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Dry skin			
subjects affected / exposed	1 / 5 (20.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Dermatitis acneiform			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Hyperhidrosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin fissures			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin indentation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Palmar-plantar erythrodysesthesia syndrome			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Scab			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Skin hyperpigmentation subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Night sweats subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Eczema subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Onycholysis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Rosacea subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Skin lesion subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Skin ulcer subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Nail disorder subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Rash macular subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Renal and urinary disorders			
Dysuria subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 2	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Haematuria subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Chromaturia			

subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Acute kidney injury			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hydronephrosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Proteinuria			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Pain in extremity			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Arthralgia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Flank pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Joint swelling			



subjects affected / exposed	1 / 5 (20.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Muscle spasms			
subjects affected / exposed	1 / 5 (20.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Muscular weakness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Bone pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Limb mass			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Spinal pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Bursitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Connective tissue disorder			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Joint range of motion decreased			

subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Osteonecrosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Osteoporosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 5 (0.00%)	2 / 10 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	3	0
Paronychia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Skin infection			
subjects affected / exposed	1 / 5 (20.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Urinary tract infection			
subjects affected / exposed	1 / 5 (20.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Wound infection			
subjects affected / exposed	1 / 5 (20.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Conjunctivitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ear infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash pustular			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1

Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Bacteraemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Cellulitis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Injection site infection subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
COVID-19 subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Coronavirus infection subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Rhinitis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Folliculitis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Herpes zoster subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Lower respiratory tract infection subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0

Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Hordeolum subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Metapneumovirus infection subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Oral candidiasis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Periorbital infection subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Urethritis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 10 (10.00%) 1	0 / 6 (0.00%) 0
Hyperglycaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 10 (10.00%) 1	0 / 6 (0.00%) 0
Hyperkalaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 10 (10.00%) 2	0 / 6 (0.00%) 0
Hypoalbuminaemia subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	1 / 10 (10.00%) 1	0 / 6 (0.00%) 0
Hypocalcaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 10 (10.00%) 1	1 / 6 (16.67%) 1
Hyponatraemia			

subjects affected / exposed	1 / 5 (20.00%)	1 / 10 (10.00%)	1 / 6 (16.67%)
occurrences (all)	1	1	1
Dehydration			
subjects affected / exposed	2 / 5 (40.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
Hypokalaemia			
subjects affected / exposed	1 / 5 (20.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Hypophosphataemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Hypercalcaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hyperuricaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypomagnesaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypoproteinaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Cachexia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Malnutrition			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Phase 1A: Cohort 7 Dose Escalation	Phase 1A: Cohort 8 Dose Escalation	Phase 1A: Cohort 9 Dose Escalation
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 3 (100.00%)	3 / 3 (100.00%)	3 / 3 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

Tumour pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Cancer pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Vascular disorders			
Hypotension subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Phlebitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Deep vein thrombosis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Hypertension subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Peripheral coldness subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Lymphoedema subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Embolism subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Hot flush subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
General disorders and administration site conditions			
Asthenia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Chills			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
Non-cardiac chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Catheter site erythema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Generalised oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nodule			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Oedema peripheral			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Secretion discharge			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Catheter site pain			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Chest discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Injection site bruising			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Localised oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Face oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Thirst			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gait disturbance			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Drug hypersensitivity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			



Balanoposthitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Breast pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Pleural effusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Dysphonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pneumothorax			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypercapnia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lung opacity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nasal dryness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pneumonitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tachypnoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hiccups			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dyspnoea exertional			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Haemoptysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Laryngeal haemorrhage subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Respiratory distress subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Psychiatric disorders			
Insomnia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Delirium subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Confusional state subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Agitation subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Mental status changes subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Anxiety subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Depression subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Mental disorder subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Sleep disorder subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Investigations			

Aspartate aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Alanine aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood bilirubin increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood cholesterol increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lipase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood glucose increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
International normalised ratio increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	2	1	0
Ammonia increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood magnesium decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ejection fraction decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Weight increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Amylase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood corticotrophin decreased			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood creatine increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood iron decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood potassium increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hepatic enzyme increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Post procedural complication			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Post procedural discharge			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Stoma site haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Post procedural contusion			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Venous injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Spinal compression fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Limb injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin abrasion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Congenital, familial and genetic disorders			
Phimosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Sinus tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Angina pectoris			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Supraventricular tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Sinus bradycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			

Dysgeusia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Memory impairment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neuralgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Migraine			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ophthalmic migraine			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Burning sensation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Post herpetic neuralgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Sciatica			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Seizure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0



Somnolence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Aphasia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Embolic stroke			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Balance disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dizziness postural			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 3 (66.67%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	3	0	0
Leukocytosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neutropenia			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Anaemia of malignant disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Thrombocytosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Iron deficiency anaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Thrombotic thrombocytopenic purpura			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Middle ear effusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tinnitus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Inner ear disorder			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Eye disorders			

Dyschromatopsia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Periorbital oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Photophobia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Vision blurred			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Visual field defect			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinal degeneration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cataract			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Diplopia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Macular detachment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinopathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Visual impairment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Central serous chorioretinopathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1

Detachment of retinal pigment epithelium			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Exophthalmos			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Subretinal fluid			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Visual acuity reduced			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eye disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Retinal detachment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Presbyopia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vitreous floaters			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blepharitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Keratitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lacrimation increased			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ocular discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Visual brightness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	2 / 3 (66.67%)	2 / 3 (66.67%)	1 / 3 (33.33%)
occurrences (all)	2	2	1
Diarrhoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	2
Constipation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	1 / 3 (33.33%)
occurrences (all)	2	1	1
Lip oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)
occurrences (all)	0	1	2
Abdominal discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ascites			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Dysphagia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastroesophageal reflux disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ileus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastric ulcer			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cheilitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oral dysaesthesia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Swollen tongue			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Abdominal pain upper			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Gastrointestinal haemorrhage subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Glossodynia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Large intestinal ulcer subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Large intestinal polyp subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Melaena subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Stomatitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Tongue oedema subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Haemorrhoids subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Retching subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Angular cheilitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Colitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Gastritis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0

Lip blister subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Odynophagia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Oesophagitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Small intestinal obstruction subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Tongue haemorrhage subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Toothache subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Hepatobiliary disorders Hepatic pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Hyperbilirubinaemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Hypertransaminasaemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Skin and subcutaneous tissue disorders Pruritus subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Rash maculo-papular subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 2	1 / 3 (33.33%) 1	0 / 3 (0.00%) 0
Alopecia			



subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Onychoclasia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin fissures			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin indentation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Palmar-plantar erythrodysesthesia syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Scab			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Skin hyperpigmentation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Onycholysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rosacea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin ulcer			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nail disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash macular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	2
Haematuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Chromaturia			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Acute kidney injury			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Hydronephrosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Proteinuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Pain in extremity			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Arthralgia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Back pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Flank pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Joint swelling			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Bone pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Limb mass			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Spinal pain			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Bursitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Connective tissue disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Joint range of motion decreased			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Osteonecrosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Osteoporosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Paronychia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Wound infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ear infection			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Rash pustular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1	0 / 3 (0.00%) 0
Bacteraemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Cellulitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Injection site infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
COVID-19 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Coronavirus infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Rhinitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Folliculitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Herpes zoster subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Lower respiratory tract infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0

Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Hordeolum subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Metapneumovirus infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Oral candidiasis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Periorbital infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Urethritis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1
Hyperglycaemia subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 5	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Hyperkalaemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Hypoalbuminaemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Hypocalcaemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Hyponatraemia			

subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	4	0	0
Dehydration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypophosphataemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypercalcaemia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hyperuricaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypomagnesaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypoproteinaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cachexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Malnutrition			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Phase 1A: Cohort 10 Dose Escalation	Phase 1A: Cohort 11 Dose Escalation	Phase 1A: Cohort 12 Dose Escalation
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 3 (100.00%)	7 / 7 (100.00%)	7 / 7 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			



Tumour pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Cancer pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Vascular disorders			
Hypotension subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 7 (14.29%) 1	1 / 7 (14.29%) 2
Phlebitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Deep vein thrombosis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1
Hypertension subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1
Peripheral coldness subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0
Lymphoedema subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Embolism subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Hot flush subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
General disorders and administration site conditions			
Asthenia subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Chills			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	2 / 3 (66.67%)	5 / 7 (71.43%)	3 / 7 (42.86%)
occurrences (all)	2	5	4
Non-cardiac chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Catheter site erythema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Generalised oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Malaise			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Nodule			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	3	0
Secretion discharge			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Catheter site pain			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Chest discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Injection site bruising			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Localised oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Face oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Thirst			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gait disturbance			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Drug hypersensitivity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			

Balanoposthitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Breast pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Pleural effusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dysphonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	1 / 7 (14.29%)
occurrences (all)	0	2	1
Epistaxis			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Nasal congestion			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Pneumothorax			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Hypercapnia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Hypoxia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Lung opacity			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Nasal dryness			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Pneumonitis			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Tachypnoea			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Hiccups			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dyspnoea exertional			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Haemoptysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Laryngeal haemorrhage subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Respiratory distress subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Psychiatric disorders			
Insomnia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0
Delirium subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Confusional state subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	1 / 7 (14.29%) 2
Agitation subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0
Mental status changes subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0
Anxiety subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Depression subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Mental disorder subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Sleep disorder subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Investigations			

Aspartate aminotransferase increased			
subjects affected / exposed	2 / 3 (66.67%)	2 / 7 (28.57%)	1 / 7 (14.29%)
occurrences (all)	2	2	1
Alanine aminotransferase increased			
subjects affected / exposed	2 / 3 (66.67%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	2	1	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	1 / 7 (14.29%)
occurrences (all)	0	1	1
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood bilirubin increased			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
Blood cholesterol increased			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Lipase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Platelet count decreased			
subjects affected / exposed	0 / 3 (0.00%)	2 / 7 (28.57%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Weight decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood glucose increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	1 / 3 (33.33%)	1 / 7 (14.29%)	1 / 7 (14.29%)
occurrences (all)	1	1	1
International normalised ratio increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Blood creatinine increased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Ammonia increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood magnesium decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Ejection fraction decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Weight increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Amylase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood corticotrophin decreased			



subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood creatine increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood iron decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood potassium increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hepatic enzyme increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Post procedural complication			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Post procedural discharge			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Stoma site haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Post procedural contusion			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Venous injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Spinal compression fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Limb injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Skin abrasion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Congenital, familial and genetic disorders			
Phimosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Sinus tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Angina pectoris			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Supraventricular tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Sinus bradycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			

Dysgeusia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Memory impairment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Neuralgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	2 / 7 (28.57%)
occurrences (all)	0	1	2
Migraine			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Ophthalmic migraine			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Burning sensation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Headache			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	1 / 7 (14.29%)
occurrences (all)	0	1	1
Neuropathy peripheral			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Post herpetic neuralgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Seizure			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0

Somnolence			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Tremor			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Aphasia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Embolic stroke			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Balance disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dizziness postural			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	3 / 7 (42.86%)
occurrences (all)	1	0	4
Leukocytosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Neutropenia			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	4
Thrombocytopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Anaemia of malignant disease			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Lymphopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Thrombocytosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Iron deficiency anaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Thrombotic thrombocytopenic purpura			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Middle ear effusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Tinnitus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Inner ear disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Eye disorders			

Dyschromatopsia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Periorbital oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Photophobia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 3 (0.00%)	3 / 7 (42.86%)	2 / 7 (28.57%)
occurrences (all)	0	3	3
Visual field defect			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Retinal degeneration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Cataract			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Diplopia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Macular detachment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Retinopathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Visual impairment			
subjects affected / exposed	0 / 3 (0.00%)	2 / 7 (28.57%)	1 / 7 (14.29%)
occurrences (all)	0	2	1
Central serous chorioretinopathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Detachment of retinal pigment epithelium			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Exophthalmos			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Subretinal fluid			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Visual acuity reduced			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Eye disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Retinal detachment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Presbyopia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Vitreous floaters			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blepharitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Keratitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Lacrimation increased			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Ocular discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Visual brightness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	2 / 3 (66.67%)	3 / 7 (42.86%)	3 / 7 (42.86%)
occurrences (all)	2	3	4
Diarrhoea			
subjects affected / exposed	1 / 3 (33.33%)	3 / 7 (42.86%)	4 / 7 (57.14%)
occurrences (all)	1	3	9
Constipation			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Abdominal pain			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	1 / 7 (14.29%)
occurrences (all)	0	1	1
Lip oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	1 / 3 (33.33%)	3 / 7 (42.86%)	1 / 7 (14.29%)
occurrences (all)	1	4	1
Abdominal discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Ascites			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Dry mouth			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0



Dysphagia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Gastroesophageal reflux disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Ileus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gastric ulcer			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	2
Abdominal distension			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Cheilitis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Dyspepsia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Oral dysaesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Swollen tongue			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Gastrointestinal haemorrhage subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Glossodynia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Large intestinal ulcer subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Large intestinal polyp subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Melaena subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Stomatitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Tongue oedema subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Haemorrhoids subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Retching subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Angular cheilitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Colitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Gastritis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0

Lip blister subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Odynophagia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Oesophagitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Small intestinal obstruction subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Tongue haemorrhage subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Toothache subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Hepatobiliary disorders Hepatic pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Hyperbilirubinaemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Hypertransaminasaemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Skin and subcutaneous tissue disorders Pruritus subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1
Rash maculo-papular subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 7 (14.29%) 2	1 / 7 (14.29%) 2
Alopecia			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Erythema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Onychoclasia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	1 / 3 (33.33%)	2 / 7 (28.57%)	0 / 7 (0.00%)
occurrences (all)	1	2	0
Dermatitis acneiform			
subjects affected / exposed	1 / 3 (33.33%)	1 / 7 (14.29%)	2 / 7 (28.57%)
occurrences (all)	1	1	2
Rash			
subjects affected / exposed	1 / 3 (33.33%)	3 / 7 (42.86%)	2 / 7 (28.57%)
occurrences (all)	1	3	2
Hyperhidrosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Skin fissures			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Skin indentation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Scab			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0

Skin hyperpigmentation subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Night sweats subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Eczema subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Onycholysis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Rosacea subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Skin lesion subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Skin ulcer subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Nail disorder subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Rash macular subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Renal and urinary disorders			
Dysuria subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Haematuria subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Chromaturia			

subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Pollakiuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Acute kidney injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hydronephrosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Proteinuria			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Urinary incontinence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Pain in extremity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Arthralgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	2 / 7 (28.57%)
occurrences (all)	0	0	2
Back pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Flank pain			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	1 / 7 (14.29%)
occurrences (all)	0	1	1
Joint swelling			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	5
Muscular weakness			
subjects affected / exposed	0 / 3 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Bone pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Limb mass			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Musculoskeletal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Myalgia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Neck pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Spinal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Bursitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Connective tissue disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Joint range of motion decreased			

subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Osteonecrosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Osteoporosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Pneumonia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
Paronychia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	2 / 7 (28.57%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Wound infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Ear infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rash pustular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0



Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Bacteraemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Cellulitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Injection site infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
COVID-19 subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Coronavirus infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Rhinitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Folliculitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Herpes zoster subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Lower respiratory tract infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0

Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Hordeolum subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Metapneumovirus infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Oral candidiasis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Periorbital infection subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Urethritis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1
Hyperglycaemia subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 2	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0
Hyperkalaemia subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Hypoalbuminaemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 7 (14.29%) 2	0 / 7 (0.00%) 0
Hypocalcaemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Hyponatraemia			

subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	3 / 7 (42.86%)
occurrences (all)	1	0	3
Dehydration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	2 / 7 (28.57%)
occurrences (all)	0	0	2
Hypokalaemia			
subjects affected / exposed	0 / 3 (0.00%)	2 / 7 (28.57%)	1 / 7 (14.29%)
occurrences (all)	0	2	1
Hypophosphataemia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	1 / 7 (14.29%)
occurrences (all)	2	0	1
Hypercalcaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hyperuricaemia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Hypomagnesaemia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Hypoproteinaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Cachexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Malnutrition			
subjects affected / exposed	0 / 3 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Phase 1B Dose Expansion	Phase 2: Cohort A	Phase 2: Cohort B
Total subjects affected by non-serious adverse events			
subjects affected / exposed	20 / 20 (100.00%)	31 / 32 (96.88%)	15 / 15 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

Tumour pain subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 32 (3.13%) 1	0 / 15 (0.00%) 0
Cancer pain subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Vascular disorders			
Hypotension subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	1 / 15 (6.67%) 1
Phlebitis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Deep vein thrombosis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Hypertension subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 32 (3.13%) 1	0 / 15 (0.00%) 0
Peripheral coldness subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Lymphoedema subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 2	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Embolism subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Hot flush subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
General disorders and administration site conditions			
Asthenia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	6 / 32 (18.75%) 7	1 / 15 (6.67%) 1
Chills			

subjects affected / exposed	3 / 20 (15.00%)	2 / 32 (6.25%)	2 / 15 (13.33%)
occurrences (all)	3	3	2
Fatigue			
subjects affected / exposed	7 / 20 (35.00%)	10 / 32 (31.25%)	4 / 15 (26.67%)
occurrences (all)	9	15	7
Non-cardiac chest pain			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Oedema			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Pyrexia			
subjects affected / exposed	4 / 20 (20.00%)	5 / 32 (15.63%)	2 / 15 (13.33%)
occurrences (all)	4	8	2
Catheter site erythema			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Generalised oedema			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Nodule			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Oedema peripheral			
subjects affected / exposed	3 / 20 (15.00%)	5 / 32 (15.63%)	1 / 15 (6.67%)
occurrences (all)	3	6	1
Secretion discharge			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Catheter site pain			

subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Chest discomfort			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Injection site bruising			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Localised oedema			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Pain			
subjects affected / exposed	1 / 20 (5.00%)	2 / 32 (6.25%)	0 / 15 (0.00%)
occurrences (all)	1	2	0
Face oedema			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Thirst			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Gait disturbance			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences (all)	1	0	1
Drug hypersensitivity			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			

Balanoposthitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Breast pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			
subjects affected / exposed	2 / 20 (10.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	2	0	0
Respiratory, thoracic and mediastinal disorders			
Pleural effusion			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Productive cough			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Cough			
subjects affected / exposed	1 / 20 (5.00%)	3 / 32 (9.38%)	1 / 15 (6.67%)
occurrences (all)	1	3	1
Dysphonia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	2 / 20 (10.00%)	3 / 32 (9.38%)	2 / 15 (13.33%)
occurrences (all)	2	3	3
Epistaxis			
subjects affected / exposed	1 / 20 (5.00%)	1 / 32 (3.13%)	1 / 15 (6.67%)
occurrences (all)	1	1	1
Nasal congestion			

subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Pneumothorax			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Hypercapnia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Lung opacity			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Nasal dryness			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Pneumonitis			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	1 / 15 (6.67%)
occurrences (all)	0	1	1
Tachypnoea			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Hiccups			
subjects affected / exposed	0 / 20 (0.00%)	2 / 32 (6.25%)	0 / 15 (0.00%)
occurrences (all)	0	2	0
Dyspnoea exertional			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Haemoptysis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1



Laryngeal haemorrhage subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	1 / 15 (6.67%) 1
Respiratory distress subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Psychiatric disorders			
Insomnia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Delirium subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Confusional state subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	1 / 15 (6.67%) 1
Agitation subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	1 / 15 (6.67%) 1
Mental status changes subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Anxiety subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 32 (3.13%) 1	0 / 15 (0.00%) 0
Depression subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Mental disorder subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	1 / 15 (6.67%) 1
Sleep disorder subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Investigations			

Aspartate aminotransferase increased			
subjects affected / exposed	2 / 20 (10.00%)	6 / 32 (18.75%)	0 / 15 (0.00%)
occurrences (all)	2	9	0
Alanine aminotransferase increased			
subjects affected / exposed	1 / 20 (5.00%)	5 / 32 (15.63%)	1 / 15 (6.67%)
occurrences (all)	1	6	1
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 20 (0.00%)	3 / 32 (9.38%)	2 / 15 (13.33%)
occurrences (all)	0	7	2
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Blood bilirubin increased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Blood cholesterol increased			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Lipase increased			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	1 / 15 (6.67%)
occurrences (all)	0	3	1
Lymphocyte count decreased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	1 / 15 (6.67%)
occurrences (all)	0	1	2
Weight decreased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	2
Blood glucose increased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			

subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences (all)	1	0	1
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
International normalised ratio increased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	1 / 20 (5.00%)	3 / 32 (9.38%)	0 / 15 (0.00%)
occurrences (all)	1	3	0
Ammonia increased			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Blood magnesium decreased			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Ejection fraction decreased			
subjects affected / exposed	1 / 20 (5.00%)	3 / 32 (9.38%)	0 / 15 (0.00%)
occurrences (all)	1	5	0
Weight increased			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 20 (0.00%)	3 / 32 (9.38%)	1 / 15 (6.67%)
occurrences (all)	0	3	1
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	2 / 15 (13.33%)
occurrences (all)	0	1	2
Amylase increased			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	1 / 15 (6.67%)
occurrences (all)	0	3	1
Blood corticotrophin decreased			

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Blood creatine increased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	1 / 15 (6.67%) 1
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	1 / 15 (6.67%) 1
Blood iron decreased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Blood potassium increased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	1 / 15 (6.67%) 1
Hepatic enzyme increased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Neutrophil count decreased subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Injury, poisoning and procedural complications			
Fall subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 32 (3.13%) 1	1 / 15 (6.67%) 1
Post procedural complication subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Post procedural discharge subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Stoma site haemorrhage subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Post procedural contusion			

subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Venous injury			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Spinal compression fracture			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Limb injury			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Skin abrasion			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Congenital, familial and genetic disorders			
Phimosis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Sinus tachycardia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Tachycardia			
subjects affected / exposed	0 / 20 (0.00%)	2 / 32 (6.25%)	0 / 15 (0.00%)
occurrences (all)	0	2	0
Angina pectoris			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Supraventricular tachycardia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Sinus bradycardia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			

Dysgeusia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	2 / 15 (13.33%)
occurrences (all)	0	0	2
Memory impairment			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Neuralgia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	1 / 20 (5.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences (all)	2	1	0
Migraine			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Ophthalmic migraine			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Burning sensation			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	2 / 20 (10.00%)	4 / 32 (12.50%)	0 / 15 (0.00%)
occurrences (all)	2	4	0
Neuropathy peripheral			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Post herpetic neuralgia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	3	0	0
Seizure			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0

Somnolence			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	1 / 15 (6.67%)
occurrences (all)	0	1	1
Tremor			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Paraesthesia			
subjects affected / exposed	2 / 20 (10.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences (all)	2	1	0
Aphasia			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	2	0	0
Embolic stroke			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Balance disorder			
subjects affected / exposed	0 / 20 (0.00%)	2 / 32 (6.25%)	0 / 15 (0.00%)
occurrences (all)	0	2	0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Syncope			
subjects affected / exposed	0 / 20 (0.00%)	2 / 32 (6.25%)	0 / 15 (0.00%)
occurrences (all)	0	2	0
Dizziness postural			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	7 / 20 (35.00%)	9 / 32 (28.13%)	3 / 15 (20.00%)
occurrences (all)	8	17	3
Leukocytosis			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Neutropenia			

subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Thrombocytopenia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Anaemia of malignant disease			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 20 (0.00%)	2 / 32 (6.25%)	0 / 15 (0.00%)
occurrences (all)	0	2	0
Thrombocytosis			
subjects affected / exposed	0 / 20 (0.00%)	2 / 32 (6.25%)	0 / 15 (0.00%)
occurrences (all)	0	2	0
Iron deficiency anaemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Thrombotic thrombocytopenic purpura			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	1 / 15 (6.67%)
occurrences (all)	0	1	1
Middle ear effusion			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Tinnitus			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Inner ear disorder			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Eye disorders			



Dyschromatopsia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Periorbital oedema			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Photophobia			
subjects affected / exposed	0 / 20 (0.00%)	2 / 32 (6.25%)	0 / 15 (0.00%)
occurrences (all)	0	2	0
Vision blurred			
subjects affected / exposed	2 / 20 (10.00%)	5 / 32 (15.63%)	0 / 15 (0.00%)
occurrences (all)	3	7	0
Visual field defect			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Retinal degeneration			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Cataract			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Diplopia			
subjects affected / exposed	2 / 20 (10.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	2	0	0
Macular detachment			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Retinopathy			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	1 / 15 (6.67%)
occurrences (all)	0	1	1
Visual impairment			
subjects affected / exposed	2 / 20 (10.00%)	1 / 32 (3.13%)	1 / 15 (6.67%)
occurrences (all)	3	1	1
Central serous chorioretinopathy			
subjects affected / exposed	0 / 20 (0.00%)	2 / 32 (6.25%)	0 / 15 (0.00%)
occurrences (all)	0	4	0

Detachment of retinal pigment epithelium			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Exophthalmos			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Subretinal fluid			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Visual acuity reduced			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Eye disorder			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Retinal detachment			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Dry eye			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Presbyopia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Vitreous floaters			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Blepharitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Keratitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Lacrimation increased			

subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Ocular discomfort			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Visual brightness			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	7 / 20 (35.00%)	10 / 32 (31.25%)	8 / 15 (53.33%)
occurrences (all)	13	15	12
Diarrhoea			
subjects affected / exposed	10 / 20 (50.00%)	19 / 32 (59.38%)	6 / 15 (40.00%)
occurrences (all)	22	40	6
Constipation			
subjects affected / exposed	3 / 20 (15.00%)	5 / 32 (15.63%)	2 / 15 (13.33%)
occurrences (all)	3	5	3
Abdominal pain			
subjects affected / exposed	5 / 20 (25.00%)	9 / 32 (28.13%)	0 / 15 (0.00%)
occurrences (all)	5	12	0
Lip oedema			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	6 / 20 (30.00%)	6 / 32 (18.75%)	4 / 15 (26.67%)
occurrences (all)	9	9	5
Abdominal discomfort			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Ascites			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Dry mouth			
subjects affected / exposed	5 / 20 (25.00%)	1 / 32 (3.13%)	1 / 15 (6.67%)
occurrences (all)	5	3	1

Dysphagia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 20 (5.00%)	1 / 32 (3.13%)	2 / 15 (13.33%)
occurrences (all)	1	1	2
Ileus			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Gastric ulcer			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	2 / 20 (10.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	2	0	0
Cheilitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 20 (0.00%)	3 / 32 (9.38%)	1 / 15 (6.67%)
occurrences (all)	0	4	1
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Oral dysaesthesia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Swollen tongue			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	2 / 20 (10.00%)	2 / 32 (6.25%)	0 / 15 (0.00%)
occurrences (all)	2	2	0
Rectal haemorrhage			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	2	0	0

Gastrointestinal haemorrhage subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Glossodynia subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Large intestinal ulcer subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Large intestinal polyp subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Melaena subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Stomatitis subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	3 / 32 (9.38%) 3	2 / 15 (13.33%) 3
Tongue oedema subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Haemorrhoids subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 32 (3.13%) 1	0 / 15 (0.00%) 0
Retching subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	1 / 15 (6.67%) 1
Angular cheilitis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Colitis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Gastritis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0

Lip blister subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Odynophagia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	1 / 15 (6.67%) 1
Oesophagitis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Small intestinal obstruction subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Tongue haemorrhage subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Toothache subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	1 / 15 (6.67%) 1
Hepatobiliary disorders Hepatic pain subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 32 (3.13%) 1	0 / 15 (0.00%) 0
Hyperbilirubinaemia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Hypertransaminaemia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Skin and subcutaneous tissue disorders Pruritus subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	6 / 32 (18.75%) 11	2 / 15 (13.33%) 2
Rash maculo-papular subjects affected / exposed occurrences (all)	4 / 20 (20.00%) 6	4 / 32 (12.50%) 4	4 / 15 (26.67%) 4
Alopecia			

subjects affected / exposed	0 / 20 (0.00%)	2 / 32 (6.25%)	1 / 15 (6.67%)
occurrences (all)	0	2	1
Erythema			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Onychoclasia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	2 / 20 (10.00%)	7 / 32 (21.88%)	1 / 15 (6.67%)
occurrences (all)	2	8	1
Dermatitis acneiform			
subjects affected / exposed	3 / 20 (15.00%)	6 / 32 (18.75%)	4 / 15 (26.67%)
occurrences (all)	3	12	4
Rash			
subjects affected / exposed	4 / 20 (20.00%)	6 / 32 (18.75%)	2 / 15 (13.33%)
occurrences (all)	4	16	2
Hyperhidrosis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Skin fissures			
subjects affected / exposed	0 / 20 (0.00%)	2 / 32 (6.25%)	0 / 15 (0.00%)
occurrences (all)	0	2	0
Skin indentation			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Palmar-plantar erythrodysesthesia syndrome			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Rash pruritic			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Scab			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0

Skin hyperpigmentation			
subjects affected / exposed	1 / 20 (5.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	1	0	0
Night sweats			
subjects affected / exposed	0 / 20 (0.00%)	2 / 32 (6.25%)	1 / 15 (6.67%)
occurrences (all)	0	3	1
Eczema			
subjects affected / exposed	0 / 20 (0.00%)	2 / 32 (6.25%)	0 / 15 (0.00%)
occurrences (all)	0	4	0
Onycholysis			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Rosacea			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Skin ulcer			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Nail disorder			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Rash macular			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Haematuria			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Chromaturia			



subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Pollakiuria subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Acute kidney injury subjects affected / exposed occurrences (all)	2 / 20 (10.00%) 2	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Hydronephrosis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Proteinuria subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Urinary incontinence subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Endocrine disorders Adrenal insufficiency subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Musculoskeletal and connective tissue disorders Pain in extremity subjects affected / exposed occurrences (all)	3 / 20 (15.00%) 4	2 / 32 (6.25%) 2	0 / 15 (0.00%) 0
Arthralgia subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	4 / 32 (12.50%) 5	1 / 15 (6.67%) 5
Back pain subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	5 / 32 (15.63%) 9	1 / 15 (6.67%) 1
Flank pain subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Joint swelling			

subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 20 (0.00%)	3 / 32 (9.38%)	0 / 15 (0.00%)
occurrences (all)	0	3	0
Muscular weakness			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Bone pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Limb mass			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	2 / 20 (10.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	2	0	0
Neck pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Spinal pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Bursitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Connective tissue disorder			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Joint range of motion decreased			

subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Osteonecrosis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Osteoporosis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Paronychia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Skin infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	3 / 20 (15.00%)	4 / 32 (12.50%)	1 / 15 (6.67%)
occurrences (all)	5	5	1
Wound infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Ear infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Rash pustular			
subjects affected / exposed	0 / 20 (0.00%)	2 / 32 (6.25%)	0 / 15 (0.00%)
occurrences (all)	0	2	0

Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	2 / 32 (6.25%) 3	0 / 15 (0.00%) 0
Bacteraemia subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Cellulitis subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Injection site infection subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
COVID-19 subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	5 / 32 (15.63%) 5	0 / 15 (0.00%) 0
Coronavirus infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 32 (3.13%) 1	0 / 15 (0.00%) 0
Rhinitis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Folliculitis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	2 / 32 (6.25%) 2	0 / 15 (0.00%) 0
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Herpes zoster subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	1 / 15 (6.67%) 1
Lower respiratory tract infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 32 (3.13%) 1	1 / 15 (6.67%) 1
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	2 / 32 (6.25%) 2	0 / 15 (0.00%) 0

Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Hordeolum subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Metapneumovirus infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Oral candidiasis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Periorbital infection subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Urethritis subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	3 / 20 (15.00%) 3	6 / 32 (18.75%) 7	5 / 15 (33.33%) 6
Hyperglycaemia subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	2 / 32 (6.25%) 3	0 / 15 (0.00%) 0
Hyperkalaemia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Hypoalbuminaemia subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	4 / 32 (12.50%) 4	0 / 15 (0.00%) 0
Hypocalcaemia subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 32 (0.00%) 0	0 / 15 (0.00%) 0
Hyponatraemia			

subjects affected / exposed	3 / 20 (15.00%)	1 / 32 (3.13%)	2 / 15 (13.33%)
occurrences (all)	4	1	2
Dehydration			
subjects affected / exposed	2 / 20 (10.00%)	2 / 32 (6.25%)	3 / 15 (20.00%)
occurrences (all)	2	2	3
Hypokalaemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Hypophosphataemia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Hypercalcaemia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 32 (3.13%)	0 / 15 (0.00%)
occurrences (all)	0	1	0
Hyperuricaemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	0 / 15 (0.00%)
occurrences (all)	0	0	0
Hypomagnesaemia			
subjects affected / exposed	0 / 20 (0.00%)	4 / 32 (12.50%)	1 / 15 (6.67%)
occurrences (all)	0	4	3
Hypoproteinaemia			
subjects affected / exposed	0 / 20 (0.00%)	2 / 32 (6.25%)	0 / 15 (0.00%)
occurrences (all)	0	4	0
Cachexia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1
Malnutrition			
subjects affected / exposed	0 / 20 (0.00%)	0 / 32 (0.00%)	1 / 15 (6.67%)
occurrences (all)	0	0	1

<b>Non-serious adverse events</b>	Phase 2: Cohort C	Phase 2: Cohort D	Phase 2: Cohort E
Total subjects affected by non-serious adverse events			
subjects affected / exposed	12 / 12 (100.00%)	9 / 9 (100.00%)	32 / 32 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			

subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	2 / 32 (6.25%)
occurrences (all)	0	0	2
Cancer pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypotension			
subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences (all)	1	0	2
Phlebitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Deep vein thrombosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	1 / 12 (8.33%)	1 / 9 (11.11%)	2 / 32 (6.25%)
occurrences (all)	3	1	2
Peripheral coldness			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Lymphoedema			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Embolism			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	2 / 32 (6.25%)
occurrences (all)	0	1	6
Chills			

subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	2 / 32 (6.25%)
occurrences (all)	0	0	2
Fatigue			
subjects affected / exposed	3 / 12 (25.00%)	5 / 9 (55.56%)	15 / 32 (46.88%)
occurrences (all)	4	6	25
Non-cardiac chest pain			
subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
Oedema			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	2 / 32 (6.25%)
occurrences (all)	0	0	2
Catheter site erythema			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Generalised oedema			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Nodule			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	1 / 12 (8.33%)	2 / 9 (22.22%)	6 / 32 (18.75%)
occurrences (all)	2	2	7
Secretion discharge			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Catheter site pain			



subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Chest discomfort			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Injection site bruising			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Localised oedema			
subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences (all)	1	0	1
Pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Face oedema			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences (all)	0	0	1
Thirst			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences (all)	0	0	1
Gait disturbance			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Drug hypersensitivity			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			

Balanoposthitis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
Breast pain			
subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
Pelvic pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Pleural effusion			
subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	6	0	0
Productive cough			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	2 / 32 (6.25%)
occurrences (all)	0	0	2
Cough			
subjects affected / exposed	0 / 12 (0.00%)	2 / 9 (22.22%)	3 / 32 (9.38%)
occurrences (all)	0	2	4
Dysphonia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	2 / 32 (6.25%)
occurrences (all)	0	0	2
Wheezing			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	2 / 12 (16.67%)	3 / 9 (33.33%)	4 / 32 (12.50%)
occurrences (all)	3	5	4
Epistaxis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	2 / 32 (6.25%)
occurrences (all)	0	0	2
Nasal congestion			

subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	2 / 32 (6.25%)
occurrences (all)	0	0	2
Pneumothorax			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Hypercapnia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	2	0	0
Lung opacity			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Nasal dryness			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Pneumonitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Tachypnoea			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Hiccups			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences (all)	0	0	1
Dyspnoea exertional			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Haemoptysis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0

Laryngeal haemorrhage subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Respiratory distress subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Psychiatric disorders			
Insomnia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	2 / 32 (6.25%) 2
Delirium subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Confusional state subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Agitation subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Mental status changes subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Anxiety subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	2 / 32 (6.25%) 2
Depression subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	1 / 32 (3.13%) 1
Mental disorder subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Sleep disorder subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 9 (11.11%) 3	0 / 32 (0.00%) 0
Investigations			

Aspartate aminotransferase increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	3 / 32 (9.38%)
occurrences (all)	0	0	6
Alanine aminotransferase increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	6 / 32 (18.75%)
occurrences (all)	0	0	11
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 12 (0.00%)	2 / 9 (22.22%)	2 / 32 (6.25%)
occurrences (all)	0	2	2
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Blood bilirubin increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Blood cholesterol increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences (all)	0	0	1
Lipase increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	3 / 32 (9.38%)
occurrences (all)	0	0	4
Weight decreased			
subjects affected / exposed	1 / 12 (8.33%)	1 / 9 (11.11%)	0 / 32 (0.00%)
occurrences (all)	1	2	0
Blood glucose increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			

subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	2 / 32 (6.25%)
occurrences (all)	0	0	2
International normalised ratio increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	2 / 32 (6.25%)
occurrences (all)	0	0	2
Blood creatinine increased			
subjects affected / exposed	0 / 12 (0.00%)	2 / 9 (22.22%)	2 / 32 (6.25%)
occurrences (all)	0	2	2
Ammonia increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Blood magnesium decreased			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	0 / 32 (0.00%)
occurrences (all)	0	2	0
Ejection fraction decreased			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	2 / 32 (6.25%)
occurrences (all)	0	1	2
Weight increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences (all)	0	0	1
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	1 / 32 (3.13%)
occurrences (all)	0	1	1
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Amylase increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Blood corticotrophin decreased			

subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
Blood creatine increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Blood iron decreased			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
Blood potassium increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Hepatic enzyme increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Post procedural complication			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Post procedural discharge			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Stoma site haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Post procedural contusion			

subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Venous injury			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Spinal compression fracture			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Limb injury			
subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
Skin abrasion			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Congenital, familial and genetic disorders			
Phimosis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
Sinus tachycardia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	4 / 32 (12.50%)
occurrences (all)	0	0	6
Tachycardia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences (all)	0	0	1
Angina pectoris			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Supraventricular tachycardia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Sinus bradycardia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	2 / 32 (6.25%)
occurrences (all)	0	0	2
Nervous system disorders			



Dysgeusia			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	1 / 32 (3.13%)
occurrences (all)	0	1	1
Memory impairment			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Neuralgia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	2 / 12 (16.67%)	1 / 9 (11.11%)	4 / 32 (12.50%)
occurrences (all)	2	1	4
Migraine			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Ophthalmic migraine			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Burning sensation			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	3 / 32 (9.38%)
occurrences (all)	0	0	3
Neuropathy peripheral			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Post herpetic neuralgia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Seizure			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0

Somnolence			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Aphasia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Embolic stroke			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Balance disorder			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences (all)	0	0	1
Syncope			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Dizziness postural			
subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	5 / 12 (41.67%)	2 / 9 (22.22%)	14 / 32 (43.75%)
occurrences (all)	8	4	42
Leukocytosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Neutropenia			

subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
Anaemia of malignant disease			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Thrombocytosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Iron deficiency anaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Thrombotic thrombocytopenic purpura			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Middle ear effusion			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Tinnitus			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Inner ear disorder			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Eye disorders			

Dyschromatopsia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Periorbital oedema			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Photophobia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	4 / 32 (12.50%)
occurrences (all)	0	1	4
Visual field defect			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Retinal degeneration			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Cataract			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences (all)	0	0	1
Diplopia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Macular detachment			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Retinopathy			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Visual impairment			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	3 / 32 (9.38%)
occurrences (all)	0	1	5
Central serous chorioretinopathy			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	0 / 32 (0.00%)
occurrences (all)	0	1	0

Detachment of retinal pigment epithelium			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Exophthalmos			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Subretinal fluid			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Visual acuity reduced			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Eye disorder			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
Retinal detachment			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
Presbyopia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences (all)	0	0	1
Vitreous floaters			
subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences (all)	1	0	1
Blepharitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Keratitis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
Lacrimation increased			

subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
Ocular discomfort			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Visual brightness			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	5 / 12 (41.67%)	4 / 9 (44.44%)	15 / 32 (46.88%)
occurrences (all)	6	6	19
Diarrhoea			
subjects affected / exposed	5 / 12 (41.67%)	6 / 9 (66.67%)	23 / 32 (71.88%)
occurrences (all)	6	10	40
Constipation			
subjects affected / exposed	0 / 12 (0.00%)	2 / 9 (22.22%)	4 / 32 (12.50%)
occurrences (all)	0	3	5
Abdominal pain			
subjects affected / exposed	0 / 12 (0.00%)	3 / 9 (33.33%)	1 / 32 (3.13%)
occurrences (all)	0	4	1
Lip oedema			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	5 / 12 (41.67%)	2 / 9 (22.22%)	13 / 32 (40.63%)
occurrences (all)	6	4	19
Abdominal discomfort			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Ascites			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences (all)	0	0	2
Dry mouth			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	2 / 32 (6.25%)
occurrences (all)	0	1	2

Dysphagia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences (all)	0	0	1
Gastroesophageal reflux disease			
subjects affected / exposed	2 / 12 (16.67%)	1 / 9 (11.11%)	0 / 32 (0.00%)
occurrences (all)	2	1	0
Ileus			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Gastric ulcer			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	2 / 32 (6.25%)
occurrences (all)	0	0	3
Cheilitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 12 (0.00%)	2 / 9 (22.22%)	5 / 32 (15.63%)
occurrences (all)	0	2	6
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Oral dysaesthesia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
Swollen tongue			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 12 (0.00%)	2 / 9 (22.22%)	2 / 32 (6.25%)
occurrences (all)	0	2	3
Rectal haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0

Gastrointestinal haemorrhage subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 9 (11.11%) 1	0 / 32 (0.00%) 0
Glossodynia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Large intestinal ulcer subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Large intestinal polyp subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Melaena subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Stomatitis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 9 (11.11%) 2	3 / 32 (9.38%) 3
Tongue oedema subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Haemorrhoids subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	2 / 32 (6.25%) 2
Retching subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Angular cheilitis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Colitis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Gastritis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0



Lip blister subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Odynophagia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Oesophagitis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 9 (11.11%) 1	0 / 32 (0.00%) 0
Small intestinal obstruction subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Tongue haemorrhage subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Toothache subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Hepatobiliary disorders Hepatic pain subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Hyperbilirubinaemia subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 2	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Hypertransaminaemia subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Skin and subcutaneous tissue disorders Pruritus subjects affected / exposed occurrences (all)	3 / 12 (25.00%) 3	1 / 9 (11.11%) 1	1 / 32 (3.13%) 2
Rash maculo-papular subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	2 / 32 (6.25%) 6
Alopecia			

subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	4 / 32 (12.50%)
occurrences (all)	0	0	5
Erythema			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
Onychoclasia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	4 / 32 (12.50%)
occurrences (all)	0	0	9
Dermatitis acneiform			
subjects affected / exposed	3 / 12 (25.00%)	1 / 9 (11.11%)	9 / 32 (28.13%)
occurrences (all)	2	1	10
Rash			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	3 / 32 (9.38%)
occurrences (all)	0	0	5
Hyperhidrosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Skin fissures			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Skin indentation			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Palmar-plantar erythrodysesthesia syndrome			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Scab			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0

Skin hyperpigmentation subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Night sweats subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Eczema subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Onycholysis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Rosacea subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Skin lesion subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Skin ulcer subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 9 (0.00%) 0	1 / 32 (3.13%) 1
Nail disorder subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 9 (11.11%) 1	0 / 32 (0.00%) 0
Rash macular subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Renal and urinary disorders			
Dysuria subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Haematuria subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	2 / 32 (6.25%) 3
Chromaturia			

subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
Acute kidney injury			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Hydronephrosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Proteinuria			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Pain in extremity			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	1 / 32 (3.13%)
occurrences (all)	0	1	1
Arthralgia			
subjects affected / exposed	1 / 12 (8.33%)	1 / 9 (11.11%)	2 / 32 (6.25%)
occurrences (all)	1	1	3
Back pain			
subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	2 / 32 (6.25%)
occurrences (all)	1	0	3
Flank pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Joint swelling			

subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	2 / 32 (6.25%)
occurrences (all)	0	0	2
Muscular weakness			
subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	2 / 32 (6.25%)
occurrences (all)	1	0	2
Bone pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Limb mass			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences (all)	0	0	1
Neck pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Spinal pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Bursitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Connective tissue disorder			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Joint range of motion decreased			

subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Osteonecrosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Osteoporosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Paronychia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences (all)	1	0	2
Skin infection			
subjects affected / exposed	0 / 12 (0.00%)	1 / 9 (11.11%)	1 / 32 (3.13%)
occurrences (all)	0	1	2
Urinary tract infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	7 / 32 (21.88%)
occurrences (all)	0	0	11
Wound infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Ear infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Rash pustular			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	1 / 32 (3.13%)
occurrences (all)	0	0	1

Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 9 (0.00%) 0	1 / 32 (3.13%) 1
Bacteraemia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Cellulitis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 9 (11.11%) 2	1 / 32 (3.13%) 1
Injection site infection subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
COVID-19 subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	2 / 32 (6.25%) 2
Coronavirus infection subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 2	2 / 9 (22.22%) 2	0 / 32 (0.00%) 0
Rhinitis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	2 / 9 (22.22%) 2	0 / 32 (0.00%) 0
Folliculitis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	1 / 32 (3.13%) 1
Herpes zoster subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Lower respiratory tract infection subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0

Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	1 / 32 (3.13%) 1
Hordeolum subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Metapneumovirus infection subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Oral candidiasis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Periorbital infection subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Urethritis subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 9 (0.00%) 0	0 / 32 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	2 / 12 (16.67%) 3	2 / 9 (22.22%) 2	9 / 32 (28.13%) 11
Hyperglycaemia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 9 (11.11%) 1	6 / 32 (18.75%) 10
Hyperkalaemia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	2 / 32 (6.25%) 3
Hypoalbuminaemia subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	1 / 9 (11.11%) 1	5 / 32 (15.63%) 5
Hypocalcaemia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 9 (0.00%) 0	2 / 32 (6.25%) 2
Hyponatraemia			



subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	5 / 32 (15.63%)
occurrences (all)	1	0	6
Dehydration			
subjects affected / exposed	1 / 12 (8.33%)	1 / 9 (11.11%)	5 / 32 (15.63%)
occurrences (all)	2	1	6
Hypokalaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Hypophosphataemia			
subjects affected / exposed	1 / 12 (8.33%)	1 / 9 (11.11%)	1 / 32 (3.13%)
occurrences (all)	1	1	1
Hypercalcaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Hyperuricaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	2 / 32 (6.25%)
occurrences (all)	0	0	2
Hypomagnesaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	7 / 32 (21.88%)
occurrences (all)	0	0	7
Hypoproteinaemia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
Cachexia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Malnutrition			
subjects affected / exposed	0 / 12 (0.00%)	0 / 9 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Phase 2: Cohort F		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	13 / 14 (92.86%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			

subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Cancer pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Phlebitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Deep vein thrombosis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Hypertension			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Peripheral coldness			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Lymphoedema			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Embolism			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Hot flush			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Chills			

subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	2		
Fatigue			
subjects affected / exposed	6 / 14 (42.86%)		
occurrences (all)	6		
Non-cardiac chest pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Oedema			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Pyrexia			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	2		
Catheter site erythema			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Generalised oedema			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Malaise			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Nodule			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Chest pain			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Oedema peripheral			
subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	6		
Secretion discharge			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Catheter site pain			

subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Chest discomfort			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Injection site bruising			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Localised oedema			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Face oedema			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Thirst			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Gait disturbance			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Peripheral swelling			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	2		
Drug hypersensitivity			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Reproductive system and breast disorders			

Balanoposthitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Breast pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Pelvic pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Pleural effusion			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Productive cough			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Cough			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Dysphonia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Oropharyngeal pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Wheezing			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Dyspnoea			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	2		
Epistaxis			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	2		
Nasal congestion			

subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Pneumothorax			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Hypercapnia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Hypoxia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Lung opacity			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Nasal dryness			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Pneumonitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Tachypnoea			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Hiccups			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Dyspnoea exertional			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Haemoptysis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		

Laryngeal haemorrhage subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Respiratory distress subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Psychiatric disorders			
Insomnia subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Delirium subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Confusional state subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Agitation subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Mental status changes subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Anxiety subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Depression subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Mental disorder subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Sleep disorder subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Investigations			

Aspartate aminotransferase increased			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	3		
Alanine aminotransferase increased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Blood bilirubin increased			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Blood cholesterol increased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Lipase increased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Lymphocyte count decreased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Platelet count decreased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Weight decreased			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Blood glucose increased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
White blood cell count decreased			



subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
International normalised ratio increased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Blood creatinine increased			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Ammonia increased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Blood magnesium decreased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Ejection fraction decreased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Weight increased			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Amylase increased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Blood corticotrophin decreased			

subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Blood creatine increased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Blood iron decreased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Blood potassium increased			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Hepatic enzyme increased			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Neutrophil count decreased			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	2		
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Post procedural complication			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Post procedural discharge			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Stoma site haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Post procedural contusion			

subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Venous injury			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Spinal compression fracture			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Limb injury			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Skin abrasion			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Congenital, familial and genetic disorders			
Phimosis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Cardiac disorders			
Sinus tachycardia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Tachycardia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Angina pectoris			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Supraventricular tachycardia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Sinus bradycardia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Nervous system disorders			

Dysgeusia			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Memory impairment			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Neuralgia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Dizziness			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Migraine			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Ophthalmic migraine			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Burning sensation			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Headache			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	2		
Neuropathy peripheral			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Post herpetic neuralgia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Sciatica			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Seizure			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		

Somnolence			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Tremor			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Paraesthesia			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Aphasia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Embolic stroke			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Balance disorder			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Syncope			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Dizziness postural			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	5 / 14 (35.71%)		
occurrences (all)	15		
Leukocytosis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Neutropenia			

subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Thrombocytopenia			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Anaemia of malignant disease			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Lymphopenia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Thrombocytosis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Iron deficiency anaemia			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Thrombotic thrombocytopenic purpura			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Middle ear effusion			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Tinnitus			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Inner ear disorder			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Eye disorders			

Dyschromatopsia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Periorbital oedema			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Photophobia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Vision blurred			
subjects affected / exposed	4 / 14 (28.57%)		
occurrences (all)	5		
Visual field defect			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Retinal degeneration			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Cataract			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Diplopia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Macular detachment			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Retinopathy			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Visual impairment			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	2		
Central serous chorioretinopathy			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		

Detachment of retinal pigment epithelium			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Exophthalmos			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Subretinal fluid			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Visual acuity reduced			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Eye disorder			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Retinal detachment			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Dry eye			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Presbyopia			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Vitreous floaters			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Blepharitis			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Keratitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Lacrimation increased			



subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Ocular discomfort			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Visual brightness			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	3		
Diarrhoea			
subjects affected / exposed	8 / 14 (57.14%)		
occurrences (all)	14		
Constipation			
subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	3		
Abdominal pain			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	2		
Lip oedema			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Vomiting			
subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	3		
Abdominal discomfort			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Ascites			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Dry mouth			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		

Dysphagia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Ileus			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Gastric ulcer			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Abdominal distension			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Cheilitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Dyspepsia			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Oral dysaesthesia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Swollen tongue			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Abdominal pain upper			
subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	6		
Rectal haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		

Gastrointestinal haemorrhage subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Glossodynia subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Large intestinal ulcer subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Large intestinal polyp subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Melaena subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Stomatitis subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Tongue oedema subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Haemorrhoids subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Retching subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Angular cheilitis subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Colitis subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Gastritis subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 2		

Lip blister subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Odynophagia subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Oesophagitis subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Small intestinal obstruction subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Tongue haemorrhage subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Toothache subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Hepatobiliary disorders Hepatic pain subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Hyperbilirubinaemia subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Hypertransaminaemia subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Skin and subcutaneous tissue disorders Pruritus subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Rash maculo-papular subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Alopecia			

subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	3		
Erythema			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Onychoclasia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Dry skin			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Dermatitis acneiform			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	2		
Rash			
subjects affected / exposed	3 / 14 (21.43%)		
occurrences (all)	6		
Hyperhidrosis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Skin fissures			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Skin indentation			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Palmar-plantar erythrodysesthesia syndrome			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Rash pruritic			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Scab			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		

Skin hyperpigmentation subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Night sweats subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Eczema subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Onycholysis subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Rosacea subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 3		
Skin lesion subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Skin ulcer subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Nail disorder subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Rash macular subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Renal and urinary disorders Dysuria subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Haematuria subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Chromaturia			

subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Pollakiuria			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Acute kidney injury			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Hydronephrosis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Proteinuria			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Urinary incontinence			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
Pain in extremity			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Arthralgia			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	7		
Back pain			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	2		
Flank pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Joint swelling			

subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Muscle spasms			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	3		
Muscular weakness			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Bone pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Limb mass			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Musculoskeletal pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Myalgia			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	2		
Neck pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Spinal pain			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Musculoskeletal chest pain			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	3		
Bursitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Connective tissue disorder			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Joint range of motion decreased			



subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Musculoskeletal stiffness			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Osteonecrosis			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Osteoporosis			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Infections and infestations			
Pneumonia			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Paronychia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Skin infection			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Urinary tract infection			
subjects affected / exposed	2 / 14 (14.29%)		
occurrences (all)	2		
Wound infection			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Conjunctivitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Ear infection			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Rash pustular			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		

Upper respiratory tract infection			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Bacteraemia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Cellulitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Injection site infection			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
COVID-19			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Coronavirus infection			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Rhinitis			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Folliculitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Gastroenteritis			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Herpes zoster			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	1		
Lower respiratory tract infection			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Nasopharyngitis			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		

Respiratory tract infection subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Hordeolum subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Metapneumovirus infection subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Oral candidiasis subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Periorbital infection subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Urethritis subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1		
Hyperglycaemia subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Hyperkalaemia subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Hypoalbuminaemia subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Hypocalcaemia subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0		
Hyponatraemia			

subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Dehydration			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Hypokalaemia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Hypophosphataemia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Hypercalcaemia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Hyperuricaemia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Hypomagnesaemia			
subjects affected / exposed	1 / 14 (7.14%)		
occurrences (all)	2		
Hypoproteinaemia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Cachexia			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		
Malnutrition			
subjects affected / exposed	0 / 14 (0.00%)		
occurrences (all)	0		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
21 February 2019	The following changes were made as per Amendment 1: The protocol was amended to introduce the new tablet dosage form of ASTX029, increase the number of study centres, add Europe as a location of study centres for Phase 1, provide newly available nonclinical study results, and allow for administration of the PiB dosage form of ASTX029 by gastrostomy tube (g-tube). Time windows were provided for certain assessments that were planned to occur at cycle visits to allow more scheduling flexibility for the subjects, investigators, and study centres without impacting subject safety.
12 July 2019	The following changes were made as per Amendment 2: The protocol was amended to evaluate dosing of ASTX029 under fasting conditions in Phase 1 Part A as a result of nonclinical data from 3 food-effect studies conducted in monkeys and dogs and preliminary clinical PK data becoming available.
31 December 2019	The following changes were made as per Amendment 3: The protocol was amended to modify Phase 2 cohorts and specify Phase 2 evaluations in preparation for initiation of Phase 2 and to remove ASTX029 tablet strength information to accommodate potential additional strengths, which were to be specified in the Investigator Brochure (IB).
21 July 2020	The following changes were made as per Amendment 4: The protocol was amended to add language regarding conducting the study during the COVID-19 pandemic to enable continuation of the study during the pandemic, to clarify that Regimen 2 may not need to be evaluated during Phase 1 Part A to determine the regimen to be evaluated in Phase 1 Part B, to specify contraceptive use and conduct of pregnancy tests consistent with requirements of countries other than the US as well as the US, to remove descriptions of the phased out ASTX029 PiB formulation.
23 May 2024	The following changes were made as per Amendment 5: A substantial amendment, updated "Astex Pharmaceuticals, Inc." and associated references to Astex to "Taiho Oncology, Inc.", "Taiho", or "the Sponsor", as a result of Astex Pharmaceuticals, Inc. becoming a wholly-owned subsidiary of Taiho Oncology Inc. as of 01 January 2024. It also inserted the End of Study definition and added the Study Extension phase.

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The ASTX029 clinical development program was terminated by the sponsor due to the changing treatment landscape.

Notes: